Author: "Akasbi M" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Akasbi M"' showing total 95 results

Start Over Author "Akasbi M"

95 results on '"Akasbi M"'

1. Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients

Author: Pérez-Alvarez, R., Brito-Zerón, P., Kostov, B., Feijoo-Massó, C., Fraile, G., Gómez-de-la-Torre, R., De-Escalante, B., López-Dupla, M., Alguacil, A., Chara-Cervantes, J., Pérez-Conesa, M., Rascón, J., Garcia-Morillo, J.S., Perez-Guerrero, P., Fonseca-Aizpuru, E., Akasbi, M., Bonet, M., Callejas, J.L., De-la-Red, G., Calvo, E., Soler, C., Peral-Gutiérrez, E., Gómez-Cerezo, J.F., Cruz-Caparrós, G., Rodríguez-Fernández, S., Pinilla, B., Gato, A., Chamorro, A.J., Morcillo, C., Robles, A., Ojeda, I., Vives, M.J., de Miguel-Campo, B., Penadés, M., De-Vicente, M., Bosch, X., Pérez-de-Lis, M., González-García, A., Yllera, C., Gracia-Tello, B., Perez-Gonzalez, A., Pedrosa-Aragón, M., Tolosa, C., Sisó-Almirall, A., Pallarés, L., and Ramos-Casals, M.
Published: 2019
Full Text: View/download PDF

2. DVT Management and Outcome Trends, 2001 to 2014

Author: Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Agudo, P., Aibar, M.A., Akasbi, M., Alcalde-Manero, M., Andújar, V., Arcelus, J.I., Ballaz, A., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Cañas, I., Casado, I., de Miguel, J., del Toro, J., Díaz, S., Díaz-Peromingo, J.A., Falgá, C., Fernández-Capitán, C., Font, C., Font, L., Gallego, P., García-Bragado, F., García-Rodenas, M., Gómez, V., González, C.J., Grau, E., Guirado, L., Gutiérrez, J., Hernández, G., Hernández-Blasco, L., Isern, V., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P.J., Martín, M., Martín-Antorán, J.M., Martín-Martos, F., Monreal, M., Morales, M.V., Nauffal, D., Nieto, J.A., Nieto, S., Núñez, M.J., Orbegoso, C., Otalora, S., Otero, R., Pagán, B., Pedrajas, J.M., Pérez, C., Pérez, G., Peris, M.L., Pons, I., Porras, J.A., Reig, O., Riera-Mestre, A., Rivas, A., Rodríguez, C., Rodríguez-Dávila, M.A., Rosa, V., Rosa-Murillo, A.S., Ruiz-Giménez, N., Sahuquillo, J.C., Sala, M.C., Sampériz, A., Sánchez, R., Sanz, O., Soler, S., Suriñach, J.M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vidal, G., Vilar, C., Villalta, J., Xifre, B., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Tomko, T., Celis, G., Salgado, E., Sánchez, G.T., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Quere, I., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Apollonio, A., Barillari, G., Bertone, A., Bilora, F., Bucherini, E., Ciammaichella, M., De Ciantis, P., Dentali, F., Di Micco, P., Duce, R., Ferrazzi, P., Grandone, E., Lessiani, G., Lodigiani, C., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Rosa, M., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Venturelli, U., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Mafalda, A., Ribeiro, J.L., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Morillo, Raquel, Jiménez, David, Aibar, Miguel Ángel, Mastroiacovo, Daniela, Wells, Philip S., Sampériz, Ángel, Saraiva de Sousa, Marta, Muriel, Alfonso, and Yusen, Roger D.
Published: 2016
Full Text: View/download PDF

3. Exposure to air pollution as an environmental determinant of how SjÃ¶gren's disease is expressed at diagnosis

Author: Brito-Zeron, P., Flores-Chavez, A., Ng, W. -F, Horvath, I. Fanny, Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Ozkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Abacar, K., Bartoloni, E., Rischmueller, M., Reis-de Oliveira, F., Trevisani, V. Fernandes Moca, Jurcut, C., Fugmann, Cecilia, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Szanto, A., Farris, A. D., Villa, M., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Inanc, N., Ramos-Casals, M., Brito-Zeron, P., Flores-Chavez, A., Ng, W. -F, Horvath, I. Fanny, Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Ozkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Abacar, K., Bartoloni, E., Rischmueller, M., Reis-de Oliveira, F., Trevisani, V. Fernandes Moca, Jurcut, C., Fugmann, Cecilia, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Szanto, A., Farris, A. D., Villa, M., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Inanc, N., and Ramos-Casals, M.
Abstract: ObjectiveTo analyse how the potential exposure to air pollutants can influence the key components at the time of diagnosis of Sjogren's phenotype (epidemiological profile, sicca symptoms, and systemic disease). MethodsFor the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Air pollution indexes per country were defined according to the OECD (1990-2021), including emission data of nitrogen and sulphur oxides (NO/SO), particulate matter (PM2.5 and 1.0), carbon monoxide (CO) and volatile organic compounds (VOC) calculated per unit of GDP, Kg per 1000 USD.ResultsThe results of the chi-square tests of independence for each air pollutant with the frequency of dry eyes at diagnosis showed that, except for one, all variables exhibited p-values <0.0001. The most pronounced disparities emerged in the dry eye prevalence among individuals inhabiting countries with the highest NO/SO exposure, a surge of 4.61 percentage points compared to other countries, followed by CO (3.59 points), non-methane (3.32 points), PM2.5 (3.30 points), and PM1.0 (1.60 points) exposures. Concerning dry mouth, individuals residing in countries with worse NO/SO exposures exhibited a heightened frequency of dry mouth by 2.05 percentage points (p<0.0001), followed by non-methane exposure (1.21 percentage points increase, p=0.007). Individuals inhabiting countries with the worst NO/SO, CO, and PM2.5 pollution levels had a higher mean global ESSDAI score than those in lower-risk nations (all p-values <0.0001). When systemic disease was stratified according to DAS into low, moderate, and high systemic activity levels, a heightened proportion of individuals manifesting moderate/severe systemic activity was observed in countries with worse exposures to NO/SO, CO, and PM2.5 pollutant levels. ConclusionFor the first time, we suggest that pollution levels could
Published: 2023
Full Text: View/download PDF

4. Influence of exposure to climate-related hazards in the phenotypic expression of primary SjÃ¶gren's syndrome

Author: Flores-Chavez, A., Brito-Zeron, P., Ng, W. -f., Szanto, A., Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Oezkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Inanc, N., Bartoloni, E., Rischmueller, M., Oliveira, F. Reis-de, Trevisani, V. Fernandes Moca, Jurcut, C., Nordmark, Gunnel, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Horvath, I. Fanny, Farris, A. D., Simoncelli, E., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Abacar, K., Ramos-Casals, M., Flores-Chavez, A., Brito-Zeron, P., Ng, W. -f., Szanto, A., Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Oezkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Inanc, N., Bartoloni, E., Rischmueller, M., Oliveira, F. Reis-de, Trevisani, V. Fernandes Moca, Jurcut, C., Nordmark, Gunnel, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Horvath, I. Fanny, Farris, A. D., Simoncelli, E., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Abacar, K., and Ramos-Casals, M.
Abstract: Objective To analyse how the key components at the time of diagnosis of the Sjogren's phenotype (epidemiological profile, sicca symptoms, and systemic disease) can be influenced by the potential exposure to climate-related natural hazards. Methods For the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Climate-related hazards per country were defined according to the OECD and included seven climate-related hazard types: extreme temperature, extreme precipitation, drought, wildfire, wind threats, river flooding, and coastal flooding. Climatic variables were defined as dichotomous variables according to whether each country is ranked among the ten countries with the most significant exposure. Results After applying data-cleaning techniques and excluding people from countries not included in the OECD climate rankings, the database study analysed 16,042 patients from 23 countries. The disease was diagnosed between 1 and 3 years earlier in people living in countries included among the top 10 worst exposed to extreme precipitation, wildfire, wind threats, river flooding, and coastal flooding. A lower frequency of dry eyes was observed in people living in countries exposed to wind threats, river flooding, and coastal flooding, with a level of statistical association being classified as strong (p<0.0001 for the three variables). The frequency of dry mouth was significantly lower in people living in countries exposed to river flooding (p<0.0001) and coastal flooding (p<0.0001). People living in countries included in the worse climate scenarios for extreme temperature (p<0.0001) and river flooding (p<0.0001) showed a higher mean ESSDAI score in comparison with people living in no-risk countries. In contrast, those living in countries exposed to worse climate scenarios for wind threats (p<0.0001) and coastal flooding
Published: 2023
Full Text: View/download PDF

5. How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients

Author: Gheitasi, H., Kostov, B., Solans, R., Fraile, G., Suárez-Cuervo, C., Casanovas, A., Rascón, F.J., Qanneta, R., Pérez-Alvarez, R., Ripoll, M., Akasbi, M., Pinilla, B., Bosch, J.A., Nava-Mateos, J., Díaz-López, B., Morera-Morales, M.L., Retamozo, S., Ramos-Casals, M., and Brito-Zerón, P.
Published: 2015
Full Text: View/download PDF

6. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Author: Marconi, V, Ramanan, A, de Bono, S, Kartman, C, Krishnan, V, Liao, R, Piruzeli, M, Goldman, J, Alatorre-Alexander, J, de Cassia Pellegrini, R, Estrada, V, Som, M, Cardoso, A, Chakladar, S, Crowe, B, Reis, P, Zhang, X, Adams, D, Ely, E, Ahn, M, Akasbi, M, Altclas, J, Ariel, F, Ariza, H, Atkar, C, Bertetti, A, Bhattacharya, M, Briones, M, Budhraja, A, Burza, A, Camacho Ortiz, A, Caricchio, R, Casas, M, Cevoli Recio, V, Choi, W, Cohen, E, Comulada-Rivera, A, Cook, P, Cornejo Juarez, D, Daniel, C, Degrecci Relvas, L, Dominguez Cherit, J, Ellerin, T, Enikeev, D, Erico Tanni Minamoto, S, Fiss, E, Furuichi, M, Giovanni Luz, K, Gonzalez, O, Gordeev, I, Gruenewald, T, Hamamoto Sato, V, Heo, E, Heo, J, Hermida, M, Hirai, Y, Hutchinson, D, Iastrebner, C, Ioachimescu, O, Jain, M, Juliani Souza Lima, M, Khan, A, Kremer, A, Lawrie, T, Macelwee, M, Madhani-Lovely, F, Malhotra, V, Martinez Resendez, M, Mckinnell, J, Milligan, P, Minelli, C, Moran Rodriguez, M, Parody, M, Paulin, P, Pellegrini, R, Pemu, P, Procopio Carvalho, A, Puoti, M, Purow, J, Ramesh, M, Rea Neto, A, Robinson, P, Rodrigues, C, Rojas Velasco, G, Saraiva, J, Scheinberg, M, Schreiber, S, Scublinsky, D, Sevciovic Grumach, A, Shawa, I, Simon Campos, J, Sofat, N, Spinner, C, Sprinz, E, Stienecker, R, Suarez, J, Tachikawa, N, Tahir, H, Tiffany, B, Vishnevsky, A, Westheimer Cavalcante, A, Zirpe, K, Marconi V. C., Ramanan A. V., de Bono S., Kartman C. E., Krishnan V., Liao R., Piruzeli M. L. B., Goldman J. D., Alatorre-Alexander J., de Cassia Pellegrini R., Estrada V., Som M., Cardoso A., Chakladar S., Crowe B., Reis P., Zhang X., Adams D. H., Ely E. W., Ahn M. -Y., Akasbi M., Altclas J. D., Ariel F., Ariza H. A., Atkar C., Bertetti A., Bhattacharya M., Briones M. L., Budhraja A., Burza A., Camacho Ortiz A., Caricchio R., Casas M., Cevoli Recio V., Choi W. S., Cohen E., Comulada-Rivera A., Cook P., Cornejo Juarez D. P., Daniel C., Degrecci Relvas L. F., Dominguez Cherit J. G., Ellerin T., Enikeev D., Erico Tanni Minamoto S., Fiss E., Furuichi M., Giovanni Luz K., Gonzalez O., Gordeev I., Gruenewald T., Hamamoto Sato V. A., Heo E. Y., Heo J. Y., Hermida M., Hirai Y., Hutchinson D., Iastrebner C., Ioachimescu O., Jain M., Juliani Souza Lima M. P., Khan A., Kremer A. E., Lawrie T., MacElwee M., Madhani-Lovely F., Malhotra V., Martinez Resendez M. F., McKinnell J., Milligan P., Minelli C., Moran Rodriguez M. A., Parody M. L., Paulin P., Pellegrini R. D. C., Pemu P., Procopio Carvalho A. C., Puoti M., Purow J., Ramesh M., Rea Neto A., Robinson P., Rodrigues C., Rojas Velasco G., Saraiva J. F. K., Scheinberg M., Schreiber S., Scublinsky D., Sevciovic Grumach A., Shawa I., Simon Campos J., Sofat N., Spinner C. D., Sprinz E., Stienecker R., Suarez J., Tachikawa N., Tahir H., Tiffany B., Vishnevsky A., Westheimer Cavalcante A., Zirpe K., Marconi, V, Ramanan, A, de Bono, S, Kartman, C, Krishnan, V, Liao, R, Piruzeli, M, Goldman, J, Alatorre-Alexander, J, de Cassia Pellegrini, R, Estrada, V, Som, M, Cardoso, A, Chakladar, S, Crowe, B, Reis, P, Zhang, X, Adams, D, Ely, E, Ahn, M, Akasbi, M, Altclas, J, Ariel, F, Ariza, H, Atkar, C, Bertetti, A, Bhattacharya, M, Briones, M, Budhraja, A, Burza, A, Camacho Ortiz, A, Caricchio, R, Casas, M, Cevoli Recio, V, Choi, W, Cohen, E, Comulada-Rivera, A, Cook, P, Cornejo Juarez, D, Daniel, C, Degrecci Relvas, L, Dominguez Cherit, J, Ellerin, T, Enikeev, D, Erico Tanni Minamoto, S, Fiss, E, Furuichi, M, Giovanni Luz, K, Gonzalez, O, Gordeev, I, Gruenewald, T, Hamamoto Sato, V, Heo, E, Heo, J, Hermida, M, Hirai, Y, Hutchinson, D, Iastrebner, C, Ioachimescu, O, Jain, M, Juliani Souza Lima, M, Khan, A, Kremer, A, Lawrie, T, Macelwee, M, Madhani-Lovely, F, Malhotra, V, Martinez Resendez, M, Mckinnell, J, Milligan, P, Minelli, C, Moran Rodriguez, M, Parody, M, Paulin, P, Pellegrini, R, Pemu, P, Procopio Carvalho, A, Puoti, M, Purow, J, Ramesh, M, Rea Neto, A, Robinson, P, Rodrigues, C, Rojas Velasco, G, Saraiva, J, Scheinberg, M, Schreiber, S, Scublinsky, D, Sevciovic Grumach, A, Shawa, I, Simon Campos, J, Sofat, N, Spinner, C, Sprinz, E, Stienecker, R, Suarez, J, Tachikawa, N, Tahir, H, Tiffany, B, Vishnevsky, A, Westheimer Cavalcante, A, Zirpe, K, Marconi V. C., Ramanan A. V., de Bono S., Kartman C. E., Krishnan V., Liao R., Piruzeli M. L. B., Goldman J. D., Alatorre-Alexander J., de Cassia Pellegrini R., Estrada V., Som M., Cardoso A., Chakladar S., Crowe B., Reis P., Zhang X., Adams D. H., Ely E. W., Ahn M. -Y., Akasbi M., Altclas J. D., Ariel F., Ariza H. A., Atkar C., Bertetti A., Bhattacharya M., Briones M. L., Budhraja A., Burza A., Camacho Ortiz A., Caricchio R., Casas M., Cevoli Recio V., Choi W. S., Cohen E., Comulada-Rivera A., Cook P., Cornejo Juarez D. P., Daniel C., Degrecci Relvas L. F., Dominguez Cherit J. G., Ellerin T., Enikeev D., Erico Tanni Minamoto S., Fiss E., Furuichi M., Giovanni Luz K., Gonzalez O., Gordeev I., Gruenewald T., Hamamoto Sato V. A., Heo E. Y., Heo J. Y., Hermida M., Hirai Y., Hutchinson D., Iastrebner C., Ioachimescu O., Jain M., Juliani Souza Lima M. P., Khan A., Kremer A. E., Lawrie T., MacElwee M., Madhani-Lovely F., Malhotra V., Martinez Resendez M. F., McKinnell J., Milligan P., Minelli C., Moran Rodriguez M. A., Parody M. L., Paulin P., Pellegrini R. D. C., Pemu P., Procopio Carvalho A. C., Puoti M., Purow J., Ramesh M., Rea Neto A., Robinson P., Rodrigues C., Rojas Velasco G., Saraiva J. F. K., Scheinberg M., Schreiber S., Scublinsky D., Sevciovic Grumach A., Shawa I., Simon Campos J., Sofat N., Spinner C. D., Sprinz E., Stienecker R., Suarez J., Tachikawa N., Tahir H., Tiffany B., Vishnevsky A., Westheimer Cavalcante A., and Zirpe K.
Abstract: Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. Methods: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027. Findings: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of −2·7 percentage points (
Published: 2021

7. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

Author: Brito-Zerón, P, Kostov, B, Solans, R, Fraile, G, Suárez-Cuervo, C, Casanovas, A, Rascón, F J, Qanneta, R, Pérez-Alvarez, R, Ripoll, M, Akasbi, M, Pinilla, B, Bosch, J A, Nava-Mateos, J, Díaz-López, B, Morera-Morales, M L, Gheitasi, H, Retamozo, S, and Ramos-Casals, M
Published: 2016
Full Text: View/download PDF

8. Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection

Author: Brito-Zeron, P., Acar-Denizli, N., Romão, V. C., Armagan, B., Seror, R., Carubbi, F., Melchor, S., Priori, R., Valim, V., Retamozo, S., Pasoto, S. G., Fernandes Moça Trevisani, V., Hofauer, B., Szántó, A., Inanc, N., Hernandez-Molina, G., Agata Sebastian, Bartoloni, E., Devauchelle-Pensec, V., Akasbi, M., Giardina, F., Bandeira, M., Sisó-Almirall, A., and Ramos-Casals, M.
Subjects: Sjogren's Syndrome, Post-Acute COVID-19 Syndrome, Rheumatology, SARS-CoV-2, Immunology, Immunology and Allergy, COVID-19, Humans, Fatigue
Abstract: To analyse the frequency and characteristics of post-COVID-19 syndrome in patients with primary Sjögren's syndrome (pSS) affected by acute SARS-CoV-2 infection.By the first week of April 2021, all centres included in the Big Data Sjögren Consortium were contacted asking for patients included in the Registry diagnosed with SARSCoV-2 infection according to the ECDC guidelines. According to the NICE definitions, symptoms related to COVID-19 were classified as acute COVID-19 (signs and symptoms for up to 4 weeks), ongoing symptomatic COVID-19 (presence of signs and symptoms from 4 to 12 weeks) and post-COVID-19 syndrome (signs and symptoms that continue for12 weeks not explained by an alternative diagnosis after a protocolized study).We identified 132 patients who were followed a mean follow-up of 137.8 days (ranging from 5 days to 388 days) after being diagnosed with COVID-19. In the last visit, 75 (57%) patients remained symptomatic: 68 (52%) remained symptomatic for more than 4 weeks fulfilling the NICE definition for ongoing symptomatic post-COVID-19, and 38 (29%) remained symptomatic for more than 12 weeks fulfilling the definition of post-COVID-19 syndrome. More than 40% of pSS patients reported the persistence of four symptoms or more, including anxiety/depression (59%), arthralgias (56%), sleep disorder (44%), fatigue (40%), anosmia (34%) and myalgias (32%). Age-sex adjusted multivariate analysis identified raised LDH levels (OR 10.36), raised CRP levels (OR 7.33), use of hydroxychloroquine (OR 3.51) and antiviral agents (OR 3.38), hospital admission (OR 8.29), mean length of hospital admission (OR 1.1) and requirement of supplemental oxygen (OR 6.94) as factors associated with a higher risk of developing post-COVID-19 syndrome. A sensitivity analysis including hospital admission in the adjusted model confirmed raised CRP levels (OR 8.6, 95% CI 1.33-104.44) and use of hydroxychloroquine (OR 2.52, 95% CI 1.00-6.47) as the key independent factors associated with an enhanced risk of developing post-COVID-19 syndrome.This is the first study that analyses the frequency and characteristics of post-COVID-19 syndrome in patients affected by a systemic autoimmune disease. We found that 57% of patients with pSS affected by COVID-19 remain symptomatic after a mean follow-up of 5 months. The risk of developing post-COVID-19 syndrome in patients who required hospitalisation was 8-times higher than in non-hospitalised patients, with baseline raised CRP levels and the use of hydroxychloroquine being independent risk factors for post-COVID-19.
Published: 2021

9. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis

Author: Brito-Zerón, P., Gracia-Tello, B., Robles, A., Alguacil, A., Bonet, M., De-Escalante, B., Noblejas-Mosso, A., Gómez-de-la-Torre, R., Akasbi, M., Pérez-de-Lis, M., Pérez-Alvarez, R., Ramos-Casals, M., and Registry, on behalf of the SarcoGEAS-SEMI
Subjects: Adult, Male, medicine.medical_specialty, SARS-Cov-2, Comorbidity, comorbidities, Microbiology, survival, Article, law.invention, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, law, Virology, Internal medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Registries, sarcoidosis, Cardiopulmonary disease, Aged, 030203 arthritis & rheumatology, Aged, 80 and over, business.industry, COVID-19, Odds ratio, Middle Aged, medicine.disease, Intensive care unit, QR1-502, Hospitalization, hospital admission, Infectious Diseases, Treatment Outcome, Cohort, Female, Sarcoidosis, France, business, Cohort study
Abstract: To analyze the clinical characteristics and outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with sarcoidosis from a large multicenter cohort from Southern Europe and to identify the risk factors associated with a more complicated infection. We searched for patients with sarcoidosis presenting with SARS-CoV-2 infection (defined according to the European Centre for Disease Prevention and Control guidelines) among those included in the SarcoGEAS Registry, a nationwide, multicenter registry of patients fulfilling the American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders 1999 classification criteria for sarcoidosis. A 2:1 age-sex-matched subset of patients with sarcoidosis without SARS-CoV-2 infection was selected as control population. Forty-five patients with SARS-CoV-2 infection were identified (28 women, mean age 55 years). Thirty-six patients presented a symptomatic SARS-CoV-2 infection and 14 were hospitalized (12 required supplemental oxygen, 2 intensive care unit admission and 1 mechanical ventilation). Four patients died due to progressive respiratory failure. Patients who required hospital admission had an older mean age (64.9 vs. 51.0 years, p = 0.006), a higher frequency of baseline comorbidities including cardiovascular disease (64% vs. 23%, p = 0.016), diabetes mellitus (43% vs. 13%, p = 0.049) and chronic liver/kidney diseases (36% vs. 0%, p = 0.002) and presented more frequently fever (79% vs. 35%, p = 0.011) and dyspnea (50% vs. 3%, p = 0.001) in comparison with patients managed at home. Age- and sex-adjusted multivariate analysis identified the age at diagnosis of SARS-Cov-2 infection as the only independent variable associated with hospitalization (adjusted odds ratio 1.18, 95% conficence interval 1.04–1.35). A baseline moderate/severe pulmonary impairment in function tests was associated with a higher rate of hospitalization but the difference was not statistically significant (50% vs. 23%, p = 0.219). A close monitoring of SARS-CoV-2 infection in elderly patients with sarcoidosis, especially in those with baseline cardiopulmonary diseases and chronic liver or renal failure, is recommended. The low frequency of severe pulmonary involvement in patients with sarcoidosis from Southern Europe may explain the weak prognostic role of baseline lung impairment in our study, in contrast to studies from other geographical areas.
Published: 2021
Full Text: View/download PDF

10. SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients

Author: Brito-Zerón, Pilar, Melchor, Sheila, Seror, Raphaèle, Priori, Roberta, Solans, Roser, Kostov, Belchin, Baldini, Chiara, Carubbi, Francesco, Callejas, Jose Luis, Guisado-Vasco, Pablo, Hernández-Molina, Gabriela, Pasoto, Sandra G, Valim, Valeria, Sisó-Almirall, Antoni, Mariette, Xavier, Carreira, Patricia, Ramos-Casals, Manuel, Brito-Zerón, P, Morcillo, C, Flores-Chávez, A, Ramos-Casals, M, Acar-Denizli, N, Horvath, I F, Szanto, A, Tarr, T, Seror, R, Mariette, X, Mandl, T, Olsson, P, Li, X, Xu, B, Baldini, C, Bombardieri, S, Gottenberg, J E, Gandolfo, S, De Vita, S, Priori, R, Giardina, F, Hernandez-Molina, G, Sánchez-Guerrero, J, Kruize, A A, Hinrichs, A, Valim, V, Isenberg, D, Solans, R, Rischmueller, M, Downie-Doyle, S, Kwok, S-K, Park, S-H, Nordmark, G, Suzuki, Y, Kawano, M, Giacomelli, R, Devauchelle-Pensec, V, Saraux, A, Hofauer, B, Knopf, A, Bootsma, H, Vissink, A, Morel, J, Vollenveider, C, Atzeni, F, Retamozo, S, Moça Trevisano, V, Armagan, B, Kilic, L, Kalyoncu, U, Pasoto, S G, Kostov, B, Sisó-Almirall, A, Consani-Fernández, S, Carubbi, F, Callejas, J L, López-Dupla, M, Pérez-Alvarez, R, Akasbi, M, Guisado-Vasco, P, Sánchez, I, Hospital Universitario 12 de Octubre [Madrid], EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), H. CIMA-Sanitas, Barcelona, CELLEX-IDIBAPS Department of Autoimmune Diseases, Barcelona, Instituto Mexicano del Seguro Social [Mexico City, Mexico] (IMSS), Universidad de Colima [Mexico], Hospital Clinic [Barcelona, Spain], İstanbul Üniversitesi, İstanbul, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, MTA-Debreceni Egyetem, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, Skåne University Hospital [Malmö, Suède], Stockholm University, Wuhan University [China], Pisa University Hospital, Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy, University Hospitals, Strasbourg, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán - National Institute of Medical Science and Nutrition Salvador Zubiran [Mexico], Federal University of Espírito Santo, University Hospital Vall d’Hebròn [Barcelona, Spain], Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut d'Investigaciones Biomèdiques August Pi i Sunye (IDIBAPS), Università degli studi di Palermo - University of Palermo, Hospitales Universitarios de Granada/Universidad de Granada, Hospital Universitario Quironsalud, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Rheumatology Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy, and Michel, Geneviève
Subjects: Male, medicine.medical_specialty, Multivariate analysis, [SDV.IMM] Life Sciences [q-bio]/Immunology, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Comorbidity, Laboratory abnormality, comorbidities, outcomes, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Internal medicine, medicine, Humans, In patient, Pharmacology (medical), 030212 general & internal medicine, Registries, Risk factor, Primary Sjögren Syndrome, AcademicSubjects/MED00360, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, business.industry, SARS-CoV-2, COVID-19, Primary SS, SARS-Cov-2, Middle Aged, medicine.disease, 3. Good health, Hospitalization, Sjogren's Syndrome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Original Article, Female, business
Abstract: Objective To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.
Published: 2020
Full Text: View/download PDF

11. SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

Author: Medicina i Cirurgia, Universitat Rovira i Virgili, Brito-Zerón P; Brito-Zerón P; Melchor S; Seror R; Seror R; Priori R; Priori R; Solans R; Solans R; Kostov B; Kostov B; Baldini C; Carubbi F; Carubbi F; Callejas JL; Guisado-Vasco P; Hernández-Molina G; Hernández-Molina G; Pasoto SG; Pasoto SG; Valim V; Valim V; Sisó-Almirall A; Sisó-Almirall A; Mariette X; Carreira P; Ramos-Casals M; Brito-Zerón P; Morcillo C; Flores-Chávez A; Acar-Denizli N; Horvath IF; Szanto A; Tarr T; Mandl T; Olsson P; Li X; Xu B; Baldini C; Bombardieri S; Gottenberg JE; Gandolfo S; De Vita S; Giardina F; Sánchez-Guerrero J; Kruize AA; Hinrichs A; Isenberg D; Rischmueller M; Downie-Doyle S; Kwok SK; Park SH; Nordmark G; Suzuki Y; Kawano M; Giacomelli R; Devauchelle-Pensec V; Saraux A; Hofauer B; Knopf A; Bootsma H; Vissink A; Morel J; Vollenveider C; Atzeni F; Retamozo S; Moça Trevisano V; Armagan B; Kilic L; Kalyoncu U; Consani-Fernández S; Callejas JL; López-Dupla M; Pérez-Alvarez R; Akasbi M; Sánchez I, Medicina i Cirurgia, Universitat Rovira i Virgili, and Brito-Zerón P; Brito-Zerón P; Melchor S; Seror R; Seror R; Priori R; Priori R; Solans R; Solans R; Kostov B; Kostov B; Baldini C; Carubbi F; Carubbi F; Callejas JL; Guisado-Vasco P; Hernández-Molina G; Hernández-Molina G; Pasoto SG; Pasoto SG; Valim V; Valim V; Sisó-Almirall A; Sisó-Almirall A; Mariette X; Carreira P; Ramos-Casals M; Brito-Zerón P; Morcillo C; Flores-Chávez A; Acar-Denizli N; Horvath IF; Szanto A; Tarr T; Mandl T; Olsson P; Li X; Xu B; Baldini C; Bombardieri S; Gottenberg JE; Gandolfo S; De Vita S; Giardina F; Sánchez-Guerrero J; Kruize AA; Hinrichs A; Isenberg D; Rischmueller M; Downie-Doyle S; Kwok SK; Park SH; Nordmark G; Suzuki Y; Kawano M; Giacomelli R; Devauchelle-Pensec V; Saraux A; Hofauer B; Knopf A; Bootsma H; Vissink A; Morel J; Vollenveider C; Atzeni F; Retamozo S; Moça Trevisano V; Armagan B; Kilic L; Kalyoncu U; Consani-Fernández S; Callejas JL; López-Dupla M; Pérez-Alvarez R; Akasbi M; Sánchez I
Abstract: Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without co
Published: 2021

12. White matter abnormalities in primary Sjögren syndrome

Author: Akasbi, M., Berenguer, J., Saiz, A., Brito-Zerón, P., Pérez-De-Lis, M., Bové, A., Diaz-Lagares, C., Retamozo, S., Blanco, Y., Perez-Alvarez, R., Bosch, X., Sisó, A., Graus, F., and Ramos-Casals, M.
Published: 2012
Full Text: View/download PDF

13. High-performance liquid chromatography of selected phenolic compounds in olive oils

Author: Akasbi, M., Shoeman, D. W., and Csallany, A. Saari
Published: 1993
Full Text: View/download PDF

14. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögrenʼs syndrome

Author: Ramos-Casals, M., Brito-Zerón, P., Yagüe, J., Akasbi, M., Bautista, R., Ruano, M., Claver, G., Gil, V., and Font, J.
Published: 2005

15. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

Author: Weinberg I., Giri J., Kolluri R., Arcelus J. I., Falga C., Soler S., Braester A., Bascunana J., Gutierrez-Guisado J., Monreal M., Adarraga M. D., Agudo P., Aibar M. A., Aibar J., Amado C., Akasbi M., Aranda C., Arenas A., Ballaz A., Barba R., Barron M., Barron-Andres B., Blanco-Molina A., Camon A. M., Carrasco C., Castro J., Cruz A. J., de Ancos C., del Toro J., Demelo P., Diaz-Pedroche M. C., Diaz-Peromingo J. A., Farfan A. I., Fernandez-Capitan C., Fidalgo M. A., Font C., Font L., Garcia M. A., Garcia-Bragado F., Garcia-Morillo M., Garcia-Raso A., Gavin O., Gayol M. C., Gil-Diaz A., Gomez V., Gonzalez-Martinez J., Grau E., Gutierrez J., Hernandez-Blasco L., Iglesias M., Jara-Palomares L., Jaras M. J., Jimenez D., Jou I., Joya M. D., Lalueza A., Lima J., Llamas P., Lobo J. L., Lopez-Jimenez L., Lopez-Miguel P., Lopez-Nunez J. J., Lopez-Reyes R., Lopez-Saez J. B., Lorente M. A., Lorenzo A., Loring M., Loscos S., Lumbierres M., Marchena P. J., Martin-Fernandez M., Martin-Guerra J. M., Martin-Romero M., Mellado M., Modesto M., Morales M. V., Nieto J. A., Nunez A., Nunez M. J., Olivares M. C., Otalora S., Otero R., Pedrajas J. M., Pellejero G., Perez-Jacoiste A., Perez-Rus G., Peris M. L., Pesce M. L., Porras J. A., Rivas A., Rodriguez-Davila M. A., Rodriguez-Fernandez L., Rodriguez-Hernandez A., Rosa V., Rosillo-Hernandez E. M., Rubio C. M., Ruiz-Alcaraz S., Ruiz-Artacho P., Ruiz-Ruiz J., Ruiz-Sada P., Sahuquillo J. C., Samperiz A., Sanchez-Munoz-Torrero J. F., Sancho T., Sanoja I. D., Soto M. J., Surinach J. M., Tapia E., Torres M. I., Trujillo-Santos J., Uresandi F., Usandizaga E., Valle R., Vela J. R., Vilar C., Gutierrez P., Vazquez F. J., Vilaseca A., Vanassche T., Vandenbriele C., Verhamme P., Yoo H. H. B., Hirmerova J., Maly R., Salgado E., Benzidia I., Bertoletti L., Bura-Riviere A., Debourdeau P., Falvo N., Farge-Bancel D., Hij A., Mahe I., Moustafa F., Brenner B., Ellis M., Tzoran I., Barillari G., Bilora F., Bortoluzzi C., Brandolin B., Bucherini E., Camerota A., Ciammaichella M., Dentali F., Di Micco P., Grandone E., Imbalzano E., Lessiani G., Maida R., Mastroiacovo D., Ngoc V., Pace F., Parisi R., Pesavento R., Pinelli M., Prandoni P., Quintavalla R., Rocci A., Siniscalchi C., Sotgiu P., Tufano A., Visona A., Gibietis V., Skride A., Strautmane S., Bosevski M., Zdraveska M., Bounameaux H., Mazzolai L., Caprini J., Bui H. M., Weinberg, I., Giri, J., Kolluri, R., Arcelus, J. I., Falga, C., Soler, S., Braester, A., Bascunana, J., Gutierrez-Guisado, J., Monreal, M., Adarraga, M. D., Agudo, P., Aibar, M. A., Aibar, J., Amado, C., Akasbi, M., Aranda, C., Arenas, A., Ballaz, A., Barba, R., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Carrasco, C., Castro, J., Cruz, A. J., de Ancos, C., del Toro, J., Demelo, P., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Farfan, A. I., Fernandez-Capitan, C., Fidalgo, M. A., Font, C., Font, L., Garcia, M. A., Garcia-Bragado, F., Garcia-Morillo, M., Garcia-Raso, A., Gavin, O., Gayol, M. C., Gil-Diaz, A., Gomez, V., Gonzalez-Martinez, J., Grau, E., Gutierrez, J., Hernandez-Blasco, L., Iglesias, M., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Jou, I., Joya, M. D., Lalueza, A., Lima, J., Llamas, P., Lobo, J. L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Loscos, S., Lumbierres, M., Marchena, P. J., Martin-Fernandez, M., Martin-Guerra, J. M., Martin-Romero, M., Mellado, M., Modesto, M., Morales, M. V., Nieto, J. A., Nunez, A., Nunez, M. J., Olivares, M. C., Otalora, S., Otero, R., Pedrajas, J. M., Pellejero, G., Perez-Jacoiste, A., Perez-Rus, G., Peris, M. L., Pesce, M. L., Porras, J. A., Rivas, A., Rodriguez-Davila, M. A., Rodriguez-Fernandez, L., Rodriguez-Hernandez, A., Rosa, V., Rosillo-Hernandez, E. M., Rubio, C. M., Ruiz-Alcaraz, S., Ruiz-Artacho, P., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J. C., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Sanoja, I. D., Soto, M. J., Surinach, J. M., Tapia, E., Torres, M. I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vilar, C., Gutierrez, P., Vazquez, F. J., Vilaseca, A., Vanassche, T., Vandenbriele, C., Verhamme, P., Yoo, H. H. B., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Debourdeau, P., Falvo, N., Farge-Bancel, D., Hij, A., Mahe, I., Moustafa, F., Brenner, B., Ellis, M., Tzoran, I., Barillari, G., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Camerota, A., Ciammaichella, M., Dentali, F., Di Micco, P., Grandone, E., Imbalzano, E., Lessiani, G., Maida, R., Mastroiacovo, D., Ngoc, V., Pace, F., Parisi, R., Pesavento, R., Pinelli, M., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Sotgiu, P., Tufano, A., Visona, A., Gibietis, V., Skride, A., Strautmane, S., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J., Bui, H. M., Vanassche, Thomas, Vandenbriele, Christophe, and Verhamme, Peter
Subjects: Male, medicine.medical_specialty, Knee Joint, Treatment duration, 030204 cardiovascular system & hematology, 03 medical and health sciences, Anticoagulation, Arthroscopy, 0302 clinical medicine, Deep vein thrombosi, Recurrence, Internal medicine, Deep vein thrombosis, medicine, Humans, cardiovascular diseases, Registries, Knee arthroscopy, Aged, Venous Thrombosis, 030222 orthopedics, Hematology, medicine.diagnostic_test, business.industry, Incidence (epidemiology), Incidence, Pulmonary embolism, Venous thromboembolism, Anticoagulants, Female, Middle Aged, Treatment Outcome, Venous Thromboembolism, Small sample, medicine.disease, Orthopedic surgery, Cardiology and Cardiovascular Medicine, business
Abstract: Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient outcomes have not been described. Patients from the "Registro Informatizado Enfermedad TromboEmbolica" who had confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, treatment and outcomes including recurrent VTE, bleeds or death were compared. A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P
Published: 2018

16. Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis

Author: Barco, S., Klok, F.A., Mahe, I., Marchena, P.J., Ballaz, A., Rubio, C.M., Adarraga, M.D., Mastroiacovo, D., Konstantinides, S.V., Monreal, M., Aibar, M.A., Aibar, J., Akasbi, M., Amado, C., Arcelus, J.I., Barba, R., Barron, M., Barron-Andres, B., Bascunana, J., Blanco-Molina, A., Camon, A.M., Carrasco, C., Castro, J., Ancos, C. de, Toro, J. del, Demelo, P., Diaz-Pedroche, M.C., Diaz-Peromingo, J.A., Encabo, M., Falga, C., Farfan, A.I., Fernandez-Aracil, C., Fernandez-Capitan, C., Fernandez-Criado, M.C., Criado, M.C., Fidalgo, M.A., Font, C., Font, L., Garcia, M., Garcia-Bragado, F., Garcia-Morillo, M., Garcia-Raso, A., Garcia-Rodenas, M.M., Gavin, O., Gil-Diaz, A., Gil-Gil, F., Guirado, L., Gomez, V., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Gutierrez, J., Hernandez-Blasco, L.M., Iglesias, M., Iglesias-Perez, C., Jara-Palomares, L., Jaras, M.J., Jimenez, D., Jou, I., Joya, M.D., Lima, J., Llamas, P., Lobo, J.L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J.J., Lopez-Reyes, R., Lopez-Saez, J.B., Lorente, M.A., Lorenzo, A., Loring, M., Lumbierres, M., Madridano, O., Maestre, A., Martin-Asenjo, M., Martin-Fernandez, M., Martin-Guerra, J.M., Mellado, M., Morales, M.V., Nieto, J.A., Nunez, M.J., Olivares, M.C., Otalora, S., Otero, R., Pedrajas, J.M., Pellejero, G., Perez-Jacoiste, A., Perez-Rus, G., Peris, M.L., Pesce, M.L., Porras, J.A., Rivas, A., Rodriguez-Davila, M.A., Rodriguez-Hernandez, A., Ruiz-Artacho, P., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J.C., Salazar, V., Samperiz, A., Sanchez-Munoz-Torrero, J.F., Sancho, T., Sanoja, I., Soler, S., Soto, M.J., Surinach, J.M., Tolosa, C., Torres, M.I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vidal, G., Gutierrez, P., Vazquez, F.J., Vilaseca, A., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Debourdeau, P., Farge-Bancel, D., Hij, A., Moustafa, F., Braester, A., Brenner, B., Ellis, M., Tzoran, I., Barillari, G., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Ciammaichella, M., Dentali, F., Micco, P. di, Grandone, E., Imbalzano, E., Lessiani, G., Maggi, F., Maida, R., Mumoli, N., Hong, N.V., Pace, F., Parisi, R., Pesavento, R., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Kigitovica, D., Skride, A., Sablinskis, K., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J., Bui, H.M., RIETE Investigators, Barco, S., Klok, F. A., Mahe, I., Marchena, P. J., Ballaz, A., Rubio, C. M., Adarraga, M. D., Mastroiacovo, D., Konstantinides, S. V., Monreal, M., and Tufano, A.
Subjects: medicine.medical_specialty, Epidemiology, Deep vein, 030204 cardiovascular system & hematology, Distal DVT, 03 medical and health sciences, 0302 clinical medicine, Deep vein thrombosi, Deep vein thrombosis, Internal medicine, medicine, cardiovascular diseases, First episode, Pregnancy, Provoking risk factors, business.industry, Cancer, Hematology, medicine.disease, Thrombosis, Pathophysiology, Pulmonary embolism, medicine.anatomical_structure, Provoking risk factor, 030220 oncology & carcinogenesis, Sex, business, Venous thromboembolism
Abstract: Background and aims Sex-specific differences exist for the initial presentation of acute venous thromboembolism (VTE): men are more likely to present with proximal deep vein thrombosis (DVT) in the lower limbs (versus pulmonary embolism [PE] or isolated distal DVT [IDDVT]) than women. We studied in detail the influence of sex, age, and VTE risk factors on the initial presentation of IDDVT versus proximal DVT. Methods A total of 24,911 patients with a first episode of objectively diagnosed acute symptomatic lower-limb DVT (without symptomatic PE) were enrolled in RIETE (years 2000–2017) and included in the present analysis. Results A total of 4266 (17.1%) patients had IDDVT. No trend for more IDDVT diagnoses was observed over time. Women aged 40–69 had a higher proportion of IDDVT, especially between 40 and 49 years (+6.7%; 95CI +3.7%; +9.9%), whereas men had more often proximal DVT. The presenting location of first acute DVT depended on sex, age, and the prevalence and type of VTE risk factors. Recent surgery was independently associated with a diagnosis of IDDVT in both women and men, whereas active cancer and pregnancy were associated with proximal DVT. Conclusions The interaction between age and VTE risk factors influences the presenting location (distal versus proximal) of the first acute lower-limb DVT observed in women and men. Our observations extend to IDDVT the concept that different clinical manifestations of acute VTE may not fully share the same pathophysiological mechanisms: this contributes to explain sex-specific prognostic differences.
Published: 2019

17. SAT0596 Thoracic involvement at diagnosis drives a differentiated clinical presentation of sarcoidosis: analysis of 1245 patients (SARCOGEAS-SEMI)

Author: Retamozo, S., primary, Brito-Zerón, P., additional, Pérez-Alvarez, R., additional, Kostov, B., additional, Feijoo Masso, C., additional, Fraile, G., additional, Gómez-de-la-Torre, R., additional, De-Escalante, B., additional, López-Dupla, M., additional, Alguacil, A., additional, Chara-Cervantes, J., additional, Pérez-Conesa, M., additional, Rascón, J., additional, Garcia-Morillo, J.S., additional, Perez-Guerrero, P., additional, Fonseca, E., additional, Akasbi, M., additional, Bonet, M., additional, Callejas, J.L., additional, De-la-Red, G., additional, Calvo, E., additional, Soler, C., additional, Peral-Gutiérrez, E., additional, Gómez-Cerezo, J.F., additional, Cruz-Caparrós, G., additional, Rodríguez-Fernández, S., additional, Pinilla, B., additional, Gato, A., additional, Rolo, A., additional, Morcillo, C., additional, Robles, A., additional, Ojeda, I., additional, Vives, M.J., additional, de-Miguel, B., additional, Penadés, M., additional, De-Vicente, M., additional, Bosch, X., additional, Pérez-de-Lis, M., additional, González-García, A., additional, Yllera, C., additional, Gracia-Tello, B., additional, Perez-Gonzalez, A., additional, Pedrosa, M., additional, Tolosa, C., additional, Pallarés, L., additional, and Ramos-Casals, M., additional
Published: 2018
Full Text: View/download PDF

18. Characterization and risk estimate of cancer in patients with primary Sjogren syndrome

Author: Medicina i Cirurgia, Universitat Rovira i Virgili, Brito-Zerón, P; Kostov, B; Fraile, G; Caravia-Durán, D; Maure, B; Rascón, FJ; Zamora, M; Casanovas, A; Lopez-Dupla, M; Ripoll, M; Pinilla, B; Fonseca, E; Akasbi, M; de la Red, G; Duarte-Millán, MA; Fanlo, P; Guisado-Vasco, P; Pérez-Alvarez, R; Chamorro, AJ; Morcillo, C; Jiménez-Heredia, I; Sánchez-Berná, I; López-Guillermo, A; Ramos-Casals, M, Medicina i Cirurgia, Universitat Rovira i Virgili, and Brito-Zerón, P; Kostov, B; Fraile, G; Caravia-Durán, D; Maure, B; Rascón, FJ; Zamora, M; Casanovas, A; Lopez-Dupla, M; Ripoll, M; Pinilla, B; Fonseca, E; Akasbi, M; de la Red, G; Duarte-Millán, MA; Fanlo, P; Guisado-Vasco, P; Pérez-Alvarez, R; Chamorro, AJ; Morcillo, C; Jiménez-Heredia, I; Sánchez-Berná, I; López-Guillermo, A; Ramos-Casals, M
Abstract: Background: The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjogren syndrome (SjS).Methods: We had analyzed the development of cancer in 1300 consecutive patients fulfilling the 2002 SjS classification criteria. The baseline clinical and immunological characteristics and systemic activity (ESSDAI scores) were assessed at diagnosis as predictors of cancer using Cox proportional hazards regression analysis adjusted for age at diagnosis and gender. The sex-and age-specific standardized incidence ratios (SIR) of cancer were estimated from 2012 Spanish mortality data.Results: After a mean follow-up of 91 months, 127 (9.8%) patients developed 133 cancers. The most frequent type of cancer was B-cell lymphoma (including 27 MALT and 19 non-MALT B-cell lymphomas). Systemic activity at diagnosis of primary SjS correlated with the risk of hematological neoplasia and cryoglobulins with a high risk of either B-cell or non-B-cell lymphoma subtypes. Patients with cytopenias had a high risk of non-MALT B-cell and non-B-cell cancer, while those with low C3 levels had a high risk of MALT lymphomas and those with monoclonal gammopathy and low C4 levels had a high risk of non-MALT lymphomas. The estimated SIR for solid cancer was 1. 13 and 11.02 for hematological cancer. SIRs for specific cancers were 36.17 for multiple myeloma and immunoproliferative diseases, 19.41 for Hodgkin lymphoma, 6.04 for other non-Hodgkin lymphomas, 5.17 for thyroid cancer, 4.81 for cancers of the lip and oral cavity, and 2.53 for stomach cancer.Conclusions: One third of cancers developed by patients with primary SjS are B-cell lymphomas. The prognostic factors identified at SjS diagnosis differed according to the subtype of B-cell lymphoma developed. Prim
Published: 2017

19. DVT Management and Outcome Trends, 2001 to 2014

Author: Morillo, Raquel, primary, Jiménez, David, additional, Aibar, Miguel Ángel, additional, Mastroiacovo, Daniela, additional, Wells, Philip S., additional, Sampériz, Ángel, additional, Saraiva de Sousa, Marta, additional, Muriel, Alfonso, additional, Yusen, Roger D., additional, Monreal, Manuel, additional, Decousus, Hervè, additional, Prandoni, Paolo, additional, Brenner, Benjamin, additional, Barba, Raquel, additional, Di Micco, Pierpaolo, additional, Bertoletti, Laurent, additional, Schellong, Sebastian, additional, Tzoran, Inna, additional, Reis, Abilio, additional, Bosevski, Marijan, additional, Bounameaux, Henri, additional, Malý, Radovan, additional, Wells, Philip, additional, Papadakis, Manolis, additional, Agudo, P., additional, Aibar, M.A., additional, Akasbi, M., additional, Alcalde-Manero, M., additional, Andújar, V., additional, Arcelus, J.I., additional, Ballaz, A., additional, Barba, R., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Bascuñana, J., additional, Blanco-Molina, A., additional, Cañas, I., additional, Casado, I., additional, de Miguel, J., additional, del Toro, J., additional, Díaz, S., additional, Díaz-Peromingo, J.A., additional, Falgá, C., additional, Fernández-Capitán, C., additional, Font, C., additional, Font, L., additional, Gallego, P., additional, García-Bragado, F., additional, García-Rodenas, M., additional, Gómez, V., additional, González, C.J., additional, Grau, E., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández, G., additional, Hernández-Blasco, L., additional, Isern, V., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorente, M.A., additional, Lorenzo, A., additional, Madridano, O., additional, Maestre, A., additional, Marchena, P.J., additional, Martín, M., additional, Martín-Antorán, J.M., additional, Martín-Martos, F., additional, Monreal, M., additional, Morales, M.V., additional, Nauffal, D., additional, Nieto, J.A., additional, Nieto, S., additional, Núñez, M.J., additional, Orbegoso, C., additional, Otalora, S., additional, Otero, R., additional, Pagán, B., additional, Pedrajas, J.M., additional, Pérez, C., additional, Pérez, G., additional, Peris, M.L., additional, Pons, I., additional, Porras, J.A., additional, Reig, O., additional, Riera-Mestre, A., additional, Rivas, A., additional, Rodríguez, C., additional, Rodríguez-Dávila, M.A., additional, Rosa, V., additional, Rosa-Murillo, A.S., additional, Ruiz-Giménez, N., additional, Sahuquillo, J.C., additional, Sala, M.C., additional, Sampériz, A., additional, Sánchez, R., additional, Sanz, O., additional, Soler, S., additional, Suriñach, J.M., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valero, B., additional, Valle, R., additional, Vela, J., additional, Vidal, G., additional, Vilar, C., additional, Villalta, J., additional, Xifre, B., additional, Vanassche, T., additional, Verhamme, P., additional, Wells, P., additional, Hirmerova, J., additional, Malý, R., additional, Tomko, T., additional, Celis, G., additional, Salgado, E., additional, Sánchez, G.T., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Farge-Bancel, D., additional, Hij, A., additional, Mahé, I., additional, Merah, A., additional, Quere, I., additional, Papadakis, M., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Apollonio, A., additional, Barillari, G., additional, Bertone, A., additional, Bilora, F., additional, Bucherini, E., additional, Ciammaichella, M., additional, De Ciantis, P., additional, Dentali, F., additional, Di Micco, P., additional, Duce, R., additional, Ferrazzi, P., additional, Grandone, E., additional, Lessiani, G., additional, Lodigiani, C., additional, Mastroiacovo, D., additional, Pace, F., additional, Pesavento, R., additional, Pinelli, M., additional, Poggio, R., additional, Prandoni, P., additional, Rosa, M., additional, Rota, L., additional, Tiraferri, E., additional, Tonello, D., additional, Tufano, A., additional, Venturelli, U., additional, Visonà, A., additional, Zalunardo, B., additional, Drucka, E., additional, Kigitovica, D., additional, Skride, A., additional, Mafalda, A., additional, Ribeiro, J.L., additional, Sousa, M.S., additional, Bosevski, M., additional, Zdraveska, M., additional, Bounameaux, H., additional, and Mazzolai, L., additional
Published: 2016
Full Text: View/download PDF

20. THU0408 How we are Treating Our Systemic Patients with Primary Sjögren Syndrome? Analysis of 1120 Patients (GEAS-SS Spanish Registry)

Author: Gheitasi, H., primary, Kostov, B., additional, Solans, R., additional, Fraile, G., additional, Suárez-Cuervo, C., additional, Casanovas, A., additional, Rascόn, F.-J., additional, Qanneta, R., additional, Pérez-Alvarez, R., additional, Ripoll, M., additional, Akasbi, M., additional, Pinilla, B., additional, Bosch, X., additional, Nava-Mateos, J., additional, Díaz-Lόpez, B., additional, Morera-Morales, L., additional, Retamozo, S., additional, Ramos-Casals, M., additional, and Brito Zeron, P., additional
Published: 2015
Full Text: View/download PDF

21. OP0088 Categorization of Baseline Systemic Activity at Diagnosis Using the Essdai Disease Activity States (DAS) in Primary Sjögren Syndrome: Association with Poor Outcomes

Author: Brito Zeron, P., primary, Kostov, B., additional, Solans, R., additional, Fraile, G., additional, Caravia-Durán, D., additional, Maure, B., additional, Rascόn, F.-J., additional, Villar-Navas, B., additional, Ripoll, M., additional, Pinilla, B., additional, Fonseca, E., additional, Akasbi, M., additional, Pérez-de-Lis, M., additional, Jiménez-Heredia, I., additional, de la Red, G., additional, Gato, A., additional, Ramentol, M., additional, Ruedas, A., additional, Díaz-Lόpez, B., additional, Pallarés, L., additional, Gheitasi, H., additional, and Ramos-Casals, M., additional
Published: 2015
Full Text: View/download PDF

22. SAT0417 Cancer and Primary SjÖgren Syndrome in 1216 Patients (GEAS-SS Registry): Systemic Activity Measured by the Essdai is Related to Hematological, but not Solid Neoplasia

Author: Brito Zeron, P., primary, Kostov, B., additional, Solans, R., additional, Fraile, G., additional, García-Pérez, A., additional, Maure, B., additional, Rascόn, F.-J., additional, Lopez-Dupla, M., additional, Ripoll, M., additional, Lόpez González-Cobos, C., additional, Fonseca, E., additional, Akasbi, M., additional, Pérez-de-Lis, M., additional, Jiménez-Heredia, I., additional, de la Red, G., additional, Gato, A., additional, Ramentol, M., additional, Ruedas, A., additional, Díaz-Lόpez, B., additional, Pallarés, L., additional, Gheitasi, H., additional, and Ramos-Casals, M., additional
Published: 2015
Full Text: View/download PDF

23. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

Author: Brito-Zerón, P, primary, Kostov, B, additional, Solans, R, additional, Fraile, G, additional, Suárez-Cuervo, C, additional, Casanovas, A, additional, Rascón, F J, additional, Qanneta, R, additional, Pérez-Alvarez, R, additional, Ripoll, M, additional, Akasbi, M, additional, Pinilla, B, additional, Bosch, J A, additional, Nava-Mateos, J, additional, Díaz-López, B, additional, Morera-Morales, M L, additional, Gheitasi, H, additional, Retamozo, S, additional, and Ramos-Casals, M, additional
Published: 2014
Full Text: View/download PDF

24. OP0213 The Degree of Activity Measured with the EULAR-SS Disease Activity Index (ESSDAI) Strongly Correlated with Death in Patients with Primary Sjogren Syndrome (GEAS-SS REGISTRY)

Author: Brito Zeron, P., primary, Retamozo, S., additional, Solans, R., additional, Fraile, G., additional, Morera-Morales, L., additional, Suárez-Cuervo, C., additional, Rascόn, F.J., additional, Qanneta, R., additional, Pérez-de-Lis, M., additional, Akasbi, M., additional, Ripoll, M., additional, Pinilla, B., additional, Kostov, B., additional, Gheitasi, H., additional, and Ramos-Casals, M., additional
Published: 2014
Full Text: View/download PDF

25. THU0298 Are Anti-La Antibodies A Potential Protection for Hepatitis C Virus Infection in SjÖGren Syndrome? Analysis in 663 Patients

Author: Brito Zeron, P., primary, Kaveri, S.V., additional, Bové, A., additional, Retamozo, S., additional, Gheitasi, H., additional, Akasbi, M., additional, Gandía, M., additional, Soto-Cárdenas, M.J., additional, Pérez-de-Lis, M., additional, Pérez-Alvarez, R., additional, Kostov, B., additional, Sisό-Almirall, A., additional, Londoño, M., additional, Forns, X., additional, and Ramos-Casals, M., additional
Published: 2014
Full Text: View/download PDF

26. Annular erythema in primary Sjögren’s syndrome: description of 43 non-Asian cases

Author: Brito-Zerón, P, primary, Retamozo, S, additional, Akasbi, M, additional, Gandía, M, additional, Perez-De-Lis, M, additional, Soto-Cardenas, M-J, additional, Diaz-Lagares, C, additional, Kostov, B, additional, Bove, A, additional, Bosch, X, additional, Perez-Alvarez, R, additional, Siso, A, additional, and Ramos-Casals, M, additional
Published: 2013
Full Text: View/download PDF

27. Clinical characterization of annular erythema in European white patients with primary Sjögren syndrome

Author: Retamozo, S., primary, Brito-Zeron, P., additional, Akasbi, M., additional, Gandia, M., additional, Perez-De-Lis, M., additional, Soto-Cardenas, M.J., additional, Kostov, B., additional, Bove, A., additional, Perez-Alvarez, R., additional, and Siso-Almirall, A., additional
Published: 2013
Full Text: View/download PDF

28. White matter abnormalities in primary Sjogren syndrome

Author: Akasbi, M., primary, Berenguer, J., additional, Saiz, A., additional, Brito-Zeron, P., additional, Perez-De-Lis, M., additional, Bove, A., additional, Diaz-Lagares, C., additional, Retamozo, S., additional, Blanco, Y., additional, Perez-Alvarez, R., additional, Bosch, X., additional, Siso, A., additional, Graus, F., additional, and Ramos-Casals, M., additional
Published: 2011
Full Text: View/download PDF

29. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients

Author: Pérez-De-Lis, M., primary, Akasbi, M., additional, Sisó, A., additional, Diez-Cascon, P., additional, Brito-Zerón, P., additional, Diaz-Lagares, C., additional, Ortiz, J., additional, Perez-Alvarez, R., additional, Ramos-Casals, M., additional, and Coca, A., additional
Published: 2010
Full Text: View/download PDF

30. P322 Osteopenia in antiretroviral naive patients with advanced HIV infection

Author: Rivas, P., primary, Górgolas, M., additional, Díaz-Curiel, M., additional, Goyenechea, A., additional, Akasbi, M., additional, Malmierca, E., additional, and Fernández-Guerrero, M.L., additional
Published: 2003
Full Text: View/download PDF

31. P252 Clinical, analytical and etiological significance of cardiac tamponade in patients with pericardial effusion

Author: Akasbi, M., primary, Alonso, J., additional, Medrano, J., additional, Aguilar, E., additional, Justo, S., additional, De La Hera, J., additional, Martín, M., additional, and Górgolas, M., additional
Published: 2003
Full Text: View/download PDF

32. Annular erythema in primary Sjögren’s syndrome: description of 43 non-Asian cases.

Author: Brito-Zerón, P, Retamozo, S, Akasbi, M, Gandía, M, Perez-De-Lis, M, Soto-Cardenas, M-J, Diaz-Lagares, C, Kostov, B, Bove, A, Bosch, X, Perez-Alvarez, R, Siso, A, and Ramos-Casals, M
Subjects: ERYTHEMA, ETHNICITY, SJOGREN'S syndrome, CUTANEOUS manifestations of general diseases, RHEUMATOID arthritis, PATIENTS
Abstract: The article examines the prevalence and characterize the main epidemiological, clinical and immunological features of annular erythema (AE) in non-Asian patients with primary Sjogren's syndrome (SS). It uses a retrospective study to search for AE in 377 Spanish patients with primary SS. It concludes that AE is not an exclusive cutaneous feature of Asian patients with primary SS and it also has a specific clinical and immunological profile in addition to the characteristic cutaneous expression.
Published: 2014
Full Text: View/download PDF

33. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome.

Author: Brito-Zerón P, Soria N, Muñoz S, Bové A, Akasbi M, Belenguer R, Sisó A, and Ramos-Casals M
Abstract: OBJECTIVE: To analyze the prevalence of neutropenia in a large cohort of patients with primary Sjögren's syndrome (SS) and its association with clinical and immunological disease expression and adverse outcomes. METHODS: The study cohort included 300 patients diagnosed with primary SS in our department between 1984 and 2002. The outcomes measured after the first laboratory evidence of neutropenia (<2.5 x 10(9)/L) were first hospital admission caused by infection, development of systemic manifestations, neoplasia, and death. RESULTS: Ninety-nine (33%) patients had neutropenia during the follow-up, which was related to neoplasia or drugs in 9 (3%) patients and was considered idiopathic in the remaining 90 (30%). Patients with neutropenia had a lower mean age at diagnosis of SS (51.9 versus 59.4 years, P < 0.001) and a higher prevalence of anti-Ro/La antibodies (53% versus 22%, P < 0.001), rheumatoid factor (49% versus 32%, P = 0.009), and low C4 levels (17% versus 8%, P = 0.044) than those without neutropenia. Patients with neutropenia had a higher incidence of hospital admission caused by infection (24% versus 9%, P = 0.002), especially those with neutropenia <1 x 10(9)/L (50% versus 9%, P = 0.002), and a higher rate of admission (log rank = 0.0023) in comparison with those without neutropenia. Agranulocytosis was found in 7 (2%) patients, predominantly related to neoplasia (5 cases). One (1%) of the 90 patients with SS-related neutropenia developed large granular lymphocyte T-cell leukemia. CONCLUSION: Neutropenia should be considered a relevant hematologic finding of primary SS, due both to its elevated prevalence and to its clinical significance (close association with anti-Ro/La antibodies, coexistence with other cytopenias, and development of severe infections). Copyright © 2009 by Elsevier Inc. [ABSTRACT FROM AUTHOR]
Published: 2009
Full Text: View/download PDF

34. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

Author: Ruiz-Irastorza, G., Garcia, M., Espinosa, G., Cabezas-Rodríguez, I., Mitjavila, F., González-León, R., Sopeña, B., Perales, I., Pinilla, B., Rodríguez-Carballeira, M., López-Dupla, J. M., Callejas, J. L., Castro, A., Tolosa, C., Sánchez-García, M. E., Pérez-Conesa, M., Navarrete-Navarrete, N., Rodríguez, A. P., Herranz, M. T., Pallarés, L., Akasbi, M., Caminal, L., JESUS CANORA, Carrasco, N., Castillo, M. J., Chamorro, A. J., Erdozain, J. G., Fonseca, E. M., Frutos, B., García, M., García-Morales, M., García-Sánchez, A. I., Gil, A., Hurtado, R., Jiménez-Alonso, J. F., Martín-Álvarez, H., Micó, M. L., Navarrete, N., Núñez-Cuerda, E., Parra, S., Sáez, L., Salvador, G., Sánchez-García, E., Serralta, G., and Villalba, M. V.

35. Bronchiectasis in primary Sjögren's syndrome: Prevalence and clinical significance

Author: Soto-Cardenas, M. -J, Perez-De-Lis, M., Bove, A., Navarro, C., Brito-Zerón, P., Diaz-Lagares, C., Gandia, M., Akasbi, M., Siso, A., Ballester, E., Torres, A., and Manuel Ramos-Casals
Subjects: Male, Comorbidity, Pneumonia, Middle Aged, Autoantigens, Bronchiectasis, Cohort Studies, Sjogren's Syndrome, Spain, Humans, Female, Tomography, X-Ray Computed, Lung, Autoantibodies
Abstract: To analyse the prevalence and clinical significance of bronchiectasis in a large series of patients with primary Sjögren's syndrome (SS) and evaluate its impact on disease expression and outcomes.The study cohort included 507 patients with primary SS. Bronchiectasis were diagnosed according to pulmonary computed tomography (CT). As a control group, we included 37 consecutive SS patients evaluated by pulmonary CT during the same study period without pulmonary involvement.Fifty primary SS patients had bronchiectasis according to the pulmonary CT. Nine patients were excluded due to non-autoimmune processes and 41 were classified as bronchiectasis associated with primary SS (40 women, mean age of 64 years). All cases of bronchiectasis were of the cylindrical type and were located in the inferior lobes in 29 cases (71%). Patients with bronchiectasis were older at diagnosis of SS (60.39 vs. 52.54 years, p=0.022) and had a higher frequency of hiatus hernia (41% vs. 16%, p=0.024) in comparison with controls. Immunologically, patients with bronchiectasis had a lower frequency of anti-Ro/SS-A antibodies (27% vs. 54%, p=0.022) but a higher frequency of anti-smooth muscle--SMAantibodies (82% vs. 60%, p=0.043). During follow-up, patients with bronchiectasis had a higher frequency of respiratory infections (56% vs. 3%, p0.001) and pneumonia (29% vs. 3%, p=0.002) in comparison with those without.Patients with primary SS and bronchiectasis are characterised by an older age, a high frequency of hiatus hernia, a specific immunologic pattern (low frequency of anti-Ro/SS-A and high frequency of anti-SMA) and during follow-up a much higher frequency of respiratory infections and pneumonia.

36. Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjogren's syndrome

Author: Retamozo, S., Akasbi, M., Brito-Zeron, P., Bosch, X., Bove, A., Perez-De-Lis, M., Jimenez, I., Soto-Cardenas, M. -J, Gandia, M., Diaz-Lagares, C., Vinas, O., Siso, A., Perez-Alvarez, R., Yague, J., and Manuel Ramos-Casals

37. The Big Data Sjögren consortium: A project for a new data science era

Author: Acar-Denizli, N., Kostov, B., Ramos-Casals, M., Brito-Zerón, P., Morcillo, C., Flores-Chávez, A., Ng, F., Horvath, I. -F, Szántó, A., Rasmussen, A., Sivils, K., Scofeld, H., Seror, R., Mariette, X., Mandl, T., Olsson, P., Li, X., Xu, B., Baldini, C., Bombardieri, S., Gottenberg, J. E., Danda, D., Sandhya, P., Quartuccio, L., Corazza, L., Vita, S., Priori, R., Minniti, A., Hernandez-Molina, G., Sánchez-Guerrero, J., Kruize, A. A., Heijden, E., Valim, V., Kvarnstrom, M., Wahren-Herlenius, M., Sene, D., Gerli, R., Bartoloni, E., Praprotnik, S., Isenberg, D., Solans, R., Rischmueller, M., Downie-Doyle, S., Kwok, S-K, Park, S-H, Nordmark, G., Suzuki, Y., Kawano, M., Giacomelli, R., Carubbi, F., Devauchelle-Pensec, V., Saraux, A., Bombardieri, M., Astorri, E., Hofauer, B., Knopf, A., Bootsma, H., Vissink, A., Hammenfors, D., Brun, J. G., Fraile, G., Carsons, S. E., Gheita, T. A., Abd El-Latif, E. M., Khalil, H. M., Morel, J., Vollenveider, C., Atzeni, F., Retamozo, S., Moça Trevisano, V., Armagan, B., Kilic, L., Kalyoncu, U., Nakamura, H., Shimizu, T., Takatani, A., Nakamura, T., Takagi, Y., Sebastian, A., Wiland, P., Pasoto, S. G., Sisó-Almirall, A., Consani-Fernández, S., Sibilia, J., Miceli-Richard, C., Nocturne, G., Benessiano, J., Dieude, P., Dubost, J-J, Fauchais, A-L, Goeb, V., Hachulla, E., Larroche, C., Le Guern, V., Puéchal, X., Perdriger, A., Rist, S., Vittecoq, O., Ravaud, P., Díaz-López, B., Feijoo, C., Pallarés, L., López-Dupla, M., Pérez-Alvarez, R., Ripoll, M., Pinilla, B., Akasbi, M., Maure, B., Fonseca, E., JESUS CANORA, La Red, G., Chamorro, A. J., Jiménez-Heredia, I., Fanlo, P., Guisado-Vasco, P., and Zamora, M.

38. Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (the GEAS-SS Registry)

Author: Flores-Chávez, A., Belchin Kostov, Solans, R., Fraile, G., Maure, B., Feijoo-Massó, C., Rascón, F. -J, Pérez-Alvarez, R., Zamora-Pasadas, M., García-Pérez, A., Lopez-Dupla, M., Duarte-Millán, M. -Á, Ripoll, M., Fonseca-Aizpuru, E., Guisado-Vasco, P., Pinilla, B., De-La-Red, G., Chamorro, A. -J, Morcillo, C., Fanlo, P., Soto-Cárdenas, M. J., Retamozo, S., Ramos-Casals, M., Brito-Zerón, P., Dem-Archi, J., Rascón, F. J., Pallarés, L., Perez-De-Lis, M., Suárez-Pérez, L., Díaz-López, B., López-Dupla, M. A., Duarte-Millán, M. A., Canora, J., Villalba, M. V., Msabri, N., La Red, G., Chamorro, A. J., Jiménez-Heredia, I., Kostov, B., Sisó-Almirall, A., Akasbi, M., García-Sanchez, I., and Miguel, B.

39. [The importance of laboratory in the diagnosis in Sjogren's syndrome]. | La importancia del laboratorio en el diagnóstico del Síndrome de Sjogren Primario

Author: Britos-Zeron, P., Bove, A., Perez-De-Lis, M., Diaz-Lagares, C., Gandia, M., Akasbi, M., Soto-Cardenas, M. J., Perez-Alvarez, R., Siso, A., and Manuel Ramos-Casals

40. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

Author: Retamozo, S., Acar-Denizli, N., Rasmussen, A., Horváth, I. F., Baldini, C., roberta priori, Sandhya, P., Hernandez-Molina, G., Armagan, B., Praprotnik, S., Kvarnstrom, M., Gerli, R., Sebastian, A., Solans, R., Rischmueller, M., Pasoto, S. G., Valim, V., Nordmark, G., Kruize, A., Nakamura, H., Hofauer, B., Giacomelli, R., Trevisani, V. F. M., Devauchelle-Pensec, V., Atzeni, F., Gheita, T. A., Consani-Fernández, S., Szántó, A., Sivils, K., Gattamelata, A., Danda, D., Kilic, L., Bartoloni, E., Bombardieri, S., Sánchez-Guerrero, J., Wahren-Herlenius, M., Mariette, X., Ramos-Casals, M., Brito-Zerón, P., Morcillo, C., Flores-Chávez, A., Ng, F., Zeher, M., Scofield, H., Seror, R., Mandl, T., Olsson, P., Li, X., Xu, B., Gottenberg, J. E., Quartuccio, L., Corazza, L., Vita, S., Colafrancesco, S., Heijden, E., Sene, D., Isenberg, D., Downie-Doyle, S., Kwok, S. -K, Park, S. -H, Suzuki, Y., Kawano, M., Carubbi, F., Saraux, A., Bombardieri, M., Astorri, E., Knopf, A., Bootsma, H., Vissink, A., Hammenfors, D., Brun, J. G., Fraile, G., Carsons, S. E., Abd El-Latif, E. M., Khalil, H. M., Morel, J., Vollenveider, C., Moça Trevisano, V., Kalyoncu, U., Shimizu, T., Takatani, A., Nakamura, T., Takagi, Y., Wiland, P., Kostov, B., Sisó-Almirall, A., Sibilia, J., Miceli-Richard, C., Nocturne, G., Benessiano, J., Dieude, P., Dubost, J. -J, Fauchais, A. -L, Goeb, V., Hachulla, E., Larroche, C., Le Guern, V., Puéchal, X., Perdriger, A., Rist, S., Vittecoq, O., Ravaud, P., Díaz-López, B., Casanovas, A., Pallarés, L., López-Dupla, M., Pérez-Alvarez, R., Ripoll, M., Pinilla, B., Akasbi, M., Maure, B., Fonseca, E., Canora, J., La Red, G., Chamorro, A. J., Jiménez-Heredia, I., Fanlo, P., Guisado-Vasco, P., and Zamora, M.

41. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjogren's syndrome

Author: Brito-Zerón, P., Akasbi, M., Bosch, X., Bové, A., Pérez-De-Lis, M., Diaz-Lagares, C., Retamozo, S., Gandía, M., Pérez-Alvarez, R., Soto-Cárdenas, M. J., Sisó, A., Valls-Sole, J., Graus, F., and Manuel Ramos-Casals

42. P252 Clinical, analytical and etiological significance of cardiac tamponade in patients with pericardial effusion

Author: Akasbi, M., Alonso, J., Medrano, J., Aguilar, E., Justo, S., De La Hera, J., Martín, M., and Górgolas, M.
Published: 2004

43. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Author: Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H Adams, E Wesley Ely, Mi-Young Ahn, Miriam Akasbi, Javier David Altclas, Federico Ariel, Horacio Alberto Ariza, Chandrasekhar Atkar, Anselmo Bertetti, Meenakshi Bhattacharya, Maria Luisa Briones, Akshay Budhraja, Aaliya Burza, Adrian Camacho Ortiz, Roberto Caricchio, Marcelo Casas, Valeria Cevoli Recio, Won Suk Choi, Emilia Cohen, Angel Comulada-Rivera, Paul Cook, Dora Patricia Cornejo Juarez, Carnevali Daniel, Luiz Fernando Degrecci Relvas, Jose Guillermo Dominguez Cherit, Todd Ellerin, Dmitry Enikeev, Suzana Erico Tanni Minamoto, Elie Fiss, Motohiko Furuichi, Kleber Giovanni Luz, Jason D. Goldman, Omar Gonzalez, Ivan Gordeev, Thomas Gruenewald, Victor Augusto Hamamoto Sato, Eun Young Heo, Jung Yeon Heo, Maria Hermida, Yuji Hirai, David Hutchinson, Claudio Iastrebner, Octavian Ioachimescu, Manish Jain, Maria Patelli Juliani Souza Lima, Akram Khan, Andreas E. Kremer, Thomas Lawrie, Mark MacElwee, Farah Madhani-Lovely, Vinay Malhotra, Michel Fernando Martínez Resendez, James McKinnell, Patrick Milligan, Cesar Minelli, Miguel Angel Moran Rodriguez, Maria Leonor Parody, Priscila Paulin, Priscilla Pemu, Ana Carolina Procopio Carvalho, Massimo Puoti, Joshua Purow, Mayur Ramesh, Alvaro Rea Neto, Philip Robinson, Cristhieni Rodrigues, Gustavo Rojas Velasco, Jose Francisco Kerr Saraiva, Morton Scheinberg, Stefan Schreiber, Dario Scublinsky, Anete Sevciovic Grumach, Imad Shawa, Jesus Simon Campos, Nidhi Sofat, Christoph D. Spinner, Eduardo Sprinz, Roger Stienecker, Jose Suarez, Natsuo Tachikawa, Hasan Tahir, Brian Tiffany, Alexander Vishnevsky, Adilson Westheimer Cavalcante, Kapil Zirpe, Marconi, V, Ramanan, A, de Bono, S, Kartman, C, Krishnan, V, Liao, R, Piruzeli, M, Goldman, J, Alatorre-Alexander, J, de Cassia Pellegrini, R, Estrada, V, Som, M, Cardoso, A, Chakladar, S, Crowe, B, Reis, P, Zhang, X, Adams, D, Ely, E, Ahn, M, Akasbi, M, Altclas, J, Ariel, F, Ariza, H, Atkar, C, Bertetti, A, Bhattacharya, M, Briones, M, Budhraja, A, Burza, A, Camacho Ortiz, A, Caricchio, R, Casas, M, Cevoli Recio, V, Choi, W, Cohen, E, Comulada-Rivera, A, Cook, P, Cornejo Juarez, D, Daniel, C, Degrecci Relvas, L, Dominguez Cherit, J, Ellerin, T, Enikeev, D, Erico Tanni Minamoto, S, Fiss, E, Furuichi, M, Giovanni Luz, K, Gonzalez, O, Gordeev, I, Gruenewald, T, Hamamoto Sato, V, Heo, E, Heo, J, Hermida, M, Hirai, Y, Hutchinson, D, Iastrebner, C, Ioachimescu, O, Jain, M, Juliani Souza Lima, M, Khan, A, Kremer, A, Lawrie, T, Macelwee, M, Madhani-Lovely, F, Malhotra, V, Martinez Resendez, M, Mckinnell, J, Milligan, P, Minelli, C, Moran Rodriguez, M, Parody, M, Paulin, P, Pellegrini, R, Pemu, P, Procopio Carvalho, A, Puoti, M, Purow, J, Ramesh, M, Rea Neto, A, Robinson, P, Rodrigues, C, Rojas Velasco, G, Saraiva, J, Scheinberg, M, Schreiber, S, Scublinsky, D, Sevciovic Grumach, A, Shawa, I, Simon Campos, J, Sofat, N, Spinner, C, Sprinz, E, Stienecker, R, Suarez, J, Tachikawa, N, Tahir, H, Tiffany, B, Vishnevsky, A, Westheimer Cavalcante, A, and Zirpe, K
Subjects: Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Asia, medicine.medical_treatment, Population, Placebo, Antiviral Agents, Corrections, Dexamethasone, Baricitinib, Double-Blind Method, Adrenal Cortex Hormones, Internal medicine, Clinical endpoint, medicine, Humans, education, Adverse effect, Mechanical ventilation, education.field_of_study, Sulfonamides, Alanine, business.industry, SARS-CoV-2, Hazard ratio, Absolute risk reduction, COVID-19, Odds ratio, Articles, South America, Adenosine Monophosphate, COVID-19 Drug Treatment, Europe, Treatment Outcome, Purines, North America, Azetidines, Pyrazoles, business
Abstract: Summary Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. Methods In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov , NCT04421027 . Findings Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of −2·7 percentage points (95% CI −7·3 to 1·9). The 28-day all-cause mortality was 8% (n=62) for baricitinib and 13% (n=100) for placebo (hazard ratio [HR] 0·57 [95% CI 0·41–0·78]; nominal p=0·0018), a 38·2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. The 60-day all-cause mortality was 10% (n=79) for baricitinib and 15% (n=116) for placebo (HR 0·62 [95% CI 0·47–0·83]; p=0·0050). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups. Interpretation Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19. Funding Eli Lilly and Company. Translations For the French, Japanese, Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
Published: 2021

44. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

Author: Brito-Zerón, Pilar, Kostov, Belchin, Fraile, Guadalupe, Caravia-Durán, Daniel, Maure, Brenda, Rascón, Francisco-Javier, Zamora, Mónica, Casanovas, Arnau, Lopez-Dupla, Miguel, Ripoll, Mar, Pinilla, Blanca, Fonseca, Eva, Akasbi, Miriam, de la Red, Gloria, Duarte-Millán, Miguel-Angel, Fanlo, Patricia, Guisado-Vasco, Pablo, Pérez-Alvarez, Roberto, Chamorro, Antonio J, Morcillo, César, Jiménez-Heredia, Iratxe, Sánchez-Berná, Isabel, López-Guillermo, Armando, Ramos-Casals, Manuel, SS Study Group GEAS-SEMI, The SS Study Group GEAS-SEMI, [Morcillo,C, Brito-Zerón,P] Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Spain. [Brito-Zerón, P: Sánchez-Berná,I, Ramos-Casals,M] Laboratory of Autoimmune Diseases Josep Font, IDIBAPS, Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain. [Kostov,B] Transversal group for research in primary care, IDIBAPS, Consorci d’Atenció Primària de Salut Barcelona Esquerre (CAPSBE), Barcelona, Spain. [Fraile,G] Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain. [Caravia-Durán,D] Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain. [Maure,B] Department of Internal Medicine, Complejo Hospitalario Universitario, Vigo, Spain. [Rascón,FJ] Department of Internal Medicine, Hospital Son Espases, Palma de Mallorca, Spain. [Zamora,M, and Sánchez-Berná,I] Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain. [Casanovas,A] Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain. [ Lopez-Dupla,M] Department of Internal Medicine, Hospital Joan XXIII, Tarragona, Spain. [Ripoll,M] Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Spain. [Pinilla,B] Department of Internal Medicine, Hospital Gregorio Marañón, Madrid, Spain. [Fonseca,E] Department of Internal Medicine, Hospital de Cabueñes, Gijón, Spain. [Akasbi,M] Department of Internal Medicine, Hospital Infanta Leonor, Madrid, Spain. [de la Red,G] Department of Internal Medicine, Hospital Esperit Sant, Santa Coloma de Gramenet, Spain. [Duarte-Millán,MA] Department of Internal Medicine, Hospital de Fuenlabrada, Fuenlabrada, Spain. [Fanlo,P] Department of Internal Medicine, Hospital Virgen del Camino, Pamplona, Spain. [Guisado-Vasco,P] Department of Internal Medicine, Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain. [Pérez-Alvarez,R] Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Spain. [Chamorro,AJ] Department of Internal Medicine, Hospital de Salamanca, Salamanca, Spain. [ Jiménez-Heredia,i] Department of Internal Medicine, Hospital de Sagunto, Valencia, Spain. [López-Guillermo,A] Department of Hematology, ICMHO, Hospital Clinic, Barcelona, Spain. [Ramos-Casals,M] Department of Medicine, University of Barcelona, Barcelona, Spain.
Subjects: Oncology, Male, Cancer Research, Pathology, Lymphoma, Databases, Factual, modelos de riesgos proporcionales, humanos, Diseases::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, Enfermedad de hodgkin, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Neoplasms, Análisis de regresión, evaluación de riesgos, Gammopatía monoclonal de relevancia indeterminada, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [Medical Subject Headings], Sjogren syndrome, Stomach cancer, estudios de cohortes, Thyroid cancer, Neoplasias de la tiroides, Multiple myeloma, mediana edad, Síndrome de sjögren, Cancer, Labio, neoplasias, anciano, Hematology, Incidence, Pronóstico, Diseases::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Disease [Medical Subject Headings], Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Protein Disorders::Hypergammaglobulinemia::Monoclonal Gammopathy of Undetermined Significance [Medical Subject Headings], lcsh:Diseases of the blood and blood-forming organs, adulto, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, humanities, pronóstico, Sjogren's Syndrome, 030220 oncology & carcinogenesis, Hematologic Neoplasms, Linfoma de células b de la zona marginal, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Globulins::Serum Globulins::Immunoglobulins::Paraproteins::Cryoglobulins [Medical Subject Headings], Female, Estudios de seguimiento, Incidencia, Anatomy::Stomatognathic System::Mouth::Lip [Medical Subject Headings], Adult, medicine.medical_specialty, Neoplasias gástricas, Lymphoma, B-Cell, lcsh:RC254-282, Risk Assessment, incidencia, 03 medical and health sciences, Crioglobulinas, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Internal medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings], medicine, Diseases::Immune System Diseases::Autoimmune Diseases::Arthritis, Rheumatoid::Sjogren's Syndrome [Medical Subject Headings], Humans, linfoma, Molecular Biology, Aged, Proportional Hazards Models, 030203 arthritis & rheumatology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Regression Analysis [Medical Subject Headings], Proportional hazards model, business.industry, lcsh:RC633-647.5, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms [Medical Subject Headings], Research, Mieloma múltiple, medicine.disease, neoplasias hematológicas, Diseases::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, B-Cell, Marginal Zone [Medical Subject Headings], Sjögren syndrome, stomatognathic diseases, Risk Estimate, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], business
Abstract: Background: The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjogren syndrome (SjS). Methods: We had analyzed the development of cancer in 1300 consecutive patients fulfilling the 2002 SjS classification criteria. The baseline clinical and immunological characteristics and systemic activity (ESSDAI scores) were assessed at diagnosis as predictors of cancer using Cox proportional hazards regression analysis adjusted for age at diagnosis and gender. The sex-and age-specific standardized incidence ratios (SIR) of cancer were estimated from 2012 Spanish mortality data. Results: After a mean follow-up of 91 months, 127 (9.8%) patients developed 133 cancers. The most frequent type of cancer was B-cell lymphoma (including 27 MALT and 19 non-MALT B-cell lymphomas). Systemic activity at diagnosis of primary SjS correlated with the risk of hematological neoplasia and cryoglobulins with a high risk of either B-cell or non-B-cell lymphoma subtypes. Patients with cytopenias had a high risk of non-MALT B-cell and non-B-cell cancer, while those with low C3 levels had a high risk of MALT lymphomas and those with monoclonal gammopathy and low C4 levels had a high risk of non-MALT lymphomas. The estimated SIR for solid cancer was 1. 13 and 11.02 for hematological cancer. SIRs for specific cancers were 36.17 for multiple myeloma and immunoproliferative diseases, 19.41 for Hodgkin lymphoma, 6.04 for other non-Hodgkin lymphomas, 5.17 for thyroid cancer, 4.81 for cancers of the lip and oral cavity, and 2.53 for stomach cancer. Conclusions: One third of cancers developed by patients with primary SjS are B-cell lymphomas. The prognostic factors identified at SjS diagnosis differed according to the subtype of B-cell lymphoma developed. Primary SjS is also associated with the development of some non-hematological cancers (thyroid, oral cavity, and stomach)., This work is supported by the Grant Fondo de Investigaciones Sanitarias (MRC, INT15/00085) and by the CERCA Programme/Generalitat de Catalunya.
Published: 2017

45. DVT Management and Outcome Trends, 2001 to 2014

Author: Raquel Morillo, David Jiménez, Miguel Ángel Aibar, Daniela Mastroiacovo, Philip S. Wells, Ángel Sampériz, Marta Saraiva de Sousa, Alfonso Muriel, Roger D. Yusen, Manuel Monreal, Hervè Decousus, Paolo Prandoni, Benjamin Brenner, Raquel Barba, Pierpaolo Di Micco, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Abilio Reis, Marijan Bosevski, Henri Bounameaux, Radovan Malý, Philip Wells, Manolis Papadakis, P. Agudo, M.A. Aibar, M. Akasbi, M. Alcalde-Manero, V. Andújar, J.I. Arcelus, A. Ballaz, R. Barba, M. Barrón, B. Barrón-Andrés, J. Bascuñana, A. Blanco-Molina, I. Cañas, I. Casado, J. de Miguel, J. del Toro, S. Díaz, J.A. Díaz-Peromingo, C. Falgá, C. Fernández-Capitán, C. Font, L. Font, P. Gallego, F. García-Bragado, M. García-Rodenas, V. Gómez, C.J. González, E. Grau, L. Guirado, J. Gutiérrez, G. Hernández, L. Hernández-Blasco, V. Isern, L. Jara-Palomares, M.J. Jaras, D. Jiménez, J.L. Lobo, L. López-Jiménez, R. López-Reyes, J.B. López-Sáez, M.A. Lorente, A. Lorenzo, O. Madridano, A. Maestre, P.J. Marchena, M. Martín, J.M. Martín-Antorán, F. Martín-Martos, M. Monreal, M.V. Morales, D. Nauffal, J.A. Nieto, S. Nieto, M.J. Núñez, C. Orbegoso, S. Otalora, R. Otero, B. Pagán, J.M. Pedrajas, C. Pérez, G. Pérez, M.L. Peris, I. Pons, J.A. Porras, O. Reig, A. Riera-Mestre, A. Rivas, C. Rodríguez, M.A. Rodríguez-Dávila, V. Rosa, A.S. Rosa-Murillo, N. Ruiz-Giménez, J.C. Sahuquillo, M.C. Sala, A. Sampériz, R. Sánchez, O. Sanz, S. Soler, J.M. Suriñach, C. Tolosa, J. Trujillo-Santos, F. Uresandi, B. Valero, R. Valle, J. Vela, G. Vidal, C. Vilar, J. Villalta, B. Xifre, T. Vanassche, P. Verhamme, P. Wells, J. Hirmerova, R. Malý, T. Tomko, G. Celis, E. Salgado, G.T. Sánchez, L. Bertoletti, A. Bura-Riviere, D. Farge-Bancel, A. Hij, I. Mahé, A. Merah, I. Quere, M. Papadakis, A. Braester, B. Brenner, I. Tzoran, A. Apollonio, G. Barillari, A. Bertone, F. Bilora, E. Bucherini, M. Ciammaichella, P. De Ciantis, F. Dentali, P. Di Micco, R. Duce, P. Ferrazzi, E. Grandone, G. Lessiani, C. Lodigiani, D. Mastroiacovo, F. Pace, R. Pesavento, M. Pinelli, R. Poggio, P. Prandoni, M. Rosa, L. Rota, E. Tiraferri, D. Tonello, A. Tufano, U. Venturelli, A. Visonà, B. Zalunardo, E. Drucka, D. Kigitovica, A. Skride, A. Mafalda, J.L. Ribeiro, M.S. Sousa, M. Bosevski, M. Zdraveska, H. Bounameaux, L. Mazzolai, Morillo, R., Jimenez, D., Aibar, M. A., Mastroiacovo, D., Wells, P. S., Samperiz, A., Saraiva de Sousa, M., Muriel, A., Yusen, R. D., Monreal, M., Decousus, H., Prandoni, P., Brenner, B., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Wells, P., Papadakis, M., Agudo, P., Akasbi, M., Alcalde-Manero, M., Andujar, V., Arcelus, J. I., Ballaz, A., Barron, M., Barron-Andres, B., Bascunana, J., Blanco-Molina, A., Canas, I., Casado, I., de Miguel, J., del Toro, J., Diaz, S., Diaz-Peromingo, J. A., Falga, C., Fernandez-Capitan, C., Font, C., Font, L., Gallego, P., Garcia-Bragado, F., Garcia-Rodenas, M., Gomez, V., Gonzalez, C. J., Grau, E., Guirado, L., Gutierrez, J., Hernandez, G., Hernandez-Blasco, L., Isern, V., Jara-Palomares, L., Jaras, M. J., Lobo, J. L., Lopez-Jimenez, L., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P. J., Martin, M., Martin-Antoran, J. M., Martin-Martos, F., Morales, M. V., Nauffal, D., Nieto, J. A., Nieto, S., Nunez, M. J., Orbegoso, C., Otalora, S., Otero, R., Pagan, B., Pedrajas, J. M., Perez, C., Perez, G., Peris, M. L., Pons, I., Porras, J. A., Reig, O., Riera-Mestre, A., Rivas, A., Rodriguez, C., Rodriguez-Davila, M. A., Rosa, V., Rosa-Murillo, A. S., Ruiz-Gimenez, N., Sahuquillo, J. C., Sala, M. C., Sanchez, R., Sanz, O., Soler, S., Surinach, J. M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vidal, G., Vilar, C., Villalta, J., Xifre, B., Vanassche, T., Verhamme, P., Hirmerova, J., Tomko, T., Celis, G., Salgado, E., Sanchez, G. T., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahe, I., Merah, A., Quere, I., Braester, A., Apollonio, A., Barillari, G., Bertone, A., Bilora, F., Bucherini, E., Ciammaichella, M., De Ciantis, P., Dentali, F., Duce, R., Ferrazzi, P., Grandone, E., Lessiani, G., Lodigiani, C., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Rosa, M., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Venturelli, U., Visona, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Mafalda, A., Ribeiro, J. L., Sousa, M. S., Zdraveska, M., and Mazzolai, L.
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Vena Cava Filters, Hemorrhage, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, Rate ratio, survival, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Cause of Death, medicine, Humans, Thrombolytic Therapy, Registries, 030212 general & internal medicine, Mortality, Population Growth, Intensive care medicine, Aged, Retrospective Studies, Aged, 80 and over, Venous Thrombosis, business.industry, Anticoagulants, Disease Management, Heparin, Low-Molecular-Weight, Length of Stay, Middle Aged, Prognosis, medicine.disease, Pulmonary embolism, Emergency medicine, Female, Cardiology and Cardiovascular Medicine, business, Venous thromboembolism, Hospital stay, DVT, prognosi
Abstract: Background A comprehensive evaluation of temporal trends in the treatment of patients who have DVT may assist with identification of modifiable factors that contribute to short-term outcomes. Methods We assessed temporal trends in length of hospital stay and use of pharmacological and interventional therapies among 26,695 adults with DVT enrolled in the Registro Informatizado de la Enfermedad TromboEmbólica registry between 2001 and 2014. We also examined temporal trends in risk-adjusted rates of all-cause, pulmonary embolism-related, and bleeding-related death to 30 days after diagnosis. Results The mean length of hospital stay decreased from 9.0 days in 2001 to 2005 to 7.6 days in 2010 to 2014 (P
Published: 2016

46. P322 Osteopenia in antiretroviral naive patients with advanced HIV infection

Author: Rivas, P., Górgolas, M., Díaz-Curiel, M., Goyenechea, A., Akasbi, M., Malmierca, E., and Fernández-Guerrero, M.L.
Published: 2004

47. Temporal relationship between sarcoidosis and malignancies in a nationwide cohort of 1942 patients.

Author: Brito-Zerón P, Flores-Chávez A, González-de-Paz L, Feijoo-Massó C, de Escalante B, González-García A, Gómez-de-la-Torre R, Policarpo-Torres G, Alguacil A, García-Morillo JS, López-Dupla M, Robles Á, Bonet M, Gómez-Lozano A, Toledo N, Chamorro A, Morcillo C, Cruz-Caparrós G, de Miguel-Campo B, Akasbi M, Fonseca-Aizpuru E, Gómez-Cerezo JF, Mas-Maresma L, Vallejo-Grijalba J, Starita-Fajardo G, Sánchez-Niño R, and Ramos-Casals M
Subjects: Humans, Female, Male, Middle Aged, Adult, Time Factors, Prognosis, Aged, Cohort Studies, Risk Factors, Databases, Factual, Sarcoidosis epidemiology, Sarcoidosis diagnosis, Sarcoidosis complications, Neoplasms epidemiology
Abstract: Purpose: To investigate the phenotype of sarcoidosis according to the time when a malignancy is diagnosed (preexisting to the diagnosis of sarcoidosis, concomitant, or sequential) and to identify prognostic factors associated with malignancies in a large cohort of patients with sarcoidosis., Methods: We searched for malignancies in the SARCOGEAS cohort, a multicenter nationwide database of consecutive patients diagnosed with sarcoidosis according to the ATS/ESC/WASOG criteria. Solid malignancies were classified using the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) nomenclature, and hematological malignancies using the 2016 WHO classification. We excluded patients with a biopsy-proven diagnosis of sarcoidosis based exclusively on demonstrating granulomas in tissues also involved by malignant cells., Results: Out of 1942 patients with sarcoidosis, 233 (12%) developed 250 malignancies, including solid (n = 173), hematological (n = 57), and both types of malignancies (n = 3). Concerning the time interval between the diagnoses of both conditions, 83 (36%) patients were diagnosed with malignancy at least 1 year before sarcoidosis diagnosis, 22 (9%) had s synchronous diagnosis of both diseases, and 118 (51%) developed malignancies at least 1 year after the diagnosis of sarcoidosis (the remaining cases developed malignancies in different time intervals). The multivariate-adjusted model showed that individuals with sarcoidosis who developed a malignancy had an hazard ratio (HR) of 2.27 [95% confidence interval (CI), 1.62-3.17] for having an asymptomatic clinical phenotype at diagnosis of sarcoidosis and that spleen (presence vs. absence: HR = 2.06; 95% CI, 1.21-3.51) and bone marrow (presence vs. absence: HR = 3.04; 95% CI, 1.77-5.24) involvements were independent predictors for the development of all-type malignancies. No predictive factors were identified when the analysis was restricted to the development of solid malignancies. The analysis limited to the development of hematological malignancies confirmed the presence of involvement in the spleen (HR = 3.73; 95% CI, 1.38-10.06) and bone marrow (presence vs. absence: HR = 8.00; 95% CI, 3.15-20.35) at the time of sarcoidosis diagnosis as predictive factors., Conclusion: It is essential to consider the synchronous or metachronous timing of the diagnosis of malignancies in people with sarcoidosis. We found that half of the malignancies were diagnosed after a diagnosis of sarcoidosis, with spleen and bone marrow involvement associated with a four to eight times higher risk of developing hematological malignancies. Key messages What is already known on this topic Malignancies are one of the comorbidities more frequently encountered in people with sarcoidosis What this study adds Malignancies occur in 12% of patients with sarcoidosis Malignancy may precede, coincide with, or follow the diagnosis of sarcoidosis One-third were identified before sarcoidosis, and half were diagnosed after Spleen and bone marrow involvement are risk factors for developing hematological malignancies How this study might affect research, practice or policy Patients with sarcoidosis should be regularly monitored for neoplasms, informed of the increased risk, and educated on early detection. Those with spleen or bone marrow involvement must be closely followed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Fellowship of Postgraduate Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Published: 2024
Full Text: View/download PDF

48. Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren's syndrome.

Author: Flores-Chávez A, Brito-Zerón P, Ng WF, Szántó A, Rasmussen A, Priori R, Baldini C, Armagan B, Özkiziltaş B, Praprotnik S, Suzuki Y, Quartuccio L, Hernández-Molina G, Inanc N, Bartoloni E, Rischmueller M, Reis-de Oliveira F, Fernandes Moça Trevisani V, Jurcut C, Nordmark G, Carubbi F, Hofauer B, Valim V, Pasoto SG, Retamozo S, Atzeni F, Fonseca-Aizpuru E, López-Dupla M, Giacomelli R, Nakamura H, Akasbi M, Thompson K, Fanny Horváth I, Farris AD, Simoncelli E, Bombardieri S, Kilic L, Tufan A, Perdan Pirkmajer K, Fujisawa Y, De Vita S, Abacar K, and Ramos-Casals M
Subjects: Humans, Phenotype, Sjogren's Syndrome diagnosis, Sjogren's Syndrome epidemiology, Sjogren's Syndrome complications, Dry Eye Syndromes
Abstract: Objectives: To analyse how the key components at the time of diagnosis of the Sjögren's phenotype (epidemiological profile, sicca symptoms, and systemic disease) can be influenced by the potential exposure to climate-related natural hazards., Methods: For the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Climate-related hazards per country were defined according to the OECD and included seven climate-related hazard types: extreme temperature, extreme precipitation, drought, wildfire, wind threats, river flooding, and coastal flooding. Climatic variables were defined as dichotomous variables according to whether each country is ranked among the ten countries with the most significant exposure., Results: After applying data-cleaning techniques and excluding people from countries not included in the OECD climate rankings, the database study analysed 16,042 patients from 23 countries. The disease was diagnosed between 1 and 3 years earlier in people living in countries included among the top 10 worst exposed to extreme precipitation, wildfire, wind threats, river flooding, and coastal flooding. A lower frequency of dry eyes was observed in people living in countries exposed to wind threats, river flooding, and coastal flooding, with a level of statistical association being classified as strong (p<0.0001 for the three variables). The frequency of dry mouth was significantly lower in people living in countries exposed to river flooding (p<0.0001) and coastal flooding (p<0.0001). People living in countries included in the worse climate scenarios for extreme temperature (p<0.0001) and river flooding (p<0.0001) showed a higher mean ESSDAI score in comparison with people living in no-risk countries. In contrast, those living in countries exposed to worse climate scenarios for wind threats (p<0.0001) and coastal flooding (p<0.0001) showed a lower mean ESSDAI score in comparison with people living in no-risk countries., Conclusions: Local exposure to extreme climate-related hazards plays a role in modulating the presentation of Sjögren across countries concerning the age at which the disease is diagnosed, the frequency of dryness, and the degree of systemic activity.
Published: 2023
Full Text: View/download PDF

49. Exposure to air pollution as an environmental determinant of how Sjögren's disease is expressed at diagnosis.

Author: Brito-Zerón P, Flores-Chávez A, Ng WF, Fanny Horváth I, Rasmussen A, Priori R, Baldini C, Armagan B, Özkiziltaş B, Praprotnik S, Suzuki Y, Quartuccio L, Hernandez-Molina G, Abacar K, Bartoloni E, Rischmueller M, Reis-de Oliveira F, Fernandes Moça Trevisani V, Jurcut C, Fugmann C, Carubbi F, Hofauer B, Valim V, Pasoto SG, Retamozo S, Atzeni F, Fonseca-Aizpuru E, López-Dupla M, Giacomelli R, Nakamura H, Akasbi M, Thompson K, Szántó A, Farris AD, Villa M, Bombardieri S, Kilic L, Tufan A, Perdan Pirkmajer K, Fujisawa Y, de Vita S, Inanc N, and Ramos-Casals M
Subjects: Humans, Particulate Matter adverse effects, Particulate Matter analysis, Environmental Exposure adverse effects, Environmental Exposure analysis, Air Pollution adverse effects, Air Pollution analysis, Air Pollutants adverse effects, Air Pollutants analysis, Sjogren's Syndrome diagnosis, Sjogren's Syndrome epidemiology, Sjogren's Syndrome etiology, Xerostomia
Abstract: Objectives: To analyse how the potential exposure to air pollutants can influence the key components at the time of diagnosis of Sjögren's phenotype (epidemiological profile, sicca symptoms, and systemic disease)., Methods: For the present study, the following variables were selected for harmonization and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Air pollution indexes per country were defined according to the OECD (1990-2021), including emission data of nitrogen and sulphur oxides (NO/SO), particulate matter (PM2.5 and 1.0), carbon monoxide (CO) and volatile organic compounds (VOC) calculated per unit of GDP, Kg per 1000 USD., Results: The results of the chi-square tests of independence for each air pollutant with the frequency of dry eyes at diagnosis showed that, except for one, all variables exhibited p-values <0.0001. The most pronounced disparities emerged in the dry eye prevalence among individuals inhabiting countries with the highest NO/SO exposure, a surge of 4.61 percentage points compared to other countries, followed by CO (3.59 points), non-methane (3.32 points), PM2.5 (3.30 points), and PM1.0 (1.60 points) exposures. Concerning dry mouth, individuals residing in countries with worse NO/SO exposures exhibited a heightened frequency of dry mouth by 2.05 percentage points (p<0.0001), followed by non-methane exposure (1.21 percentage points increase, p=0.007). Individuals inhabiting countries with the worst NO/SO, CO, and PM2.5 pollution levels had a higher mean global ESSDAI score than those in lower-risk nations (all p-values <0.0001). When systemic disease was stratified according to DAS into low, moderate, and high systemic activity levels, a heightened proportion of individuals manifesting moderate/severe systemic activity was observed in countries with worse exposures to NO/SO, CO, and PM2.5 pollutant levels., Conclusions: For the first time, we suggest that pollution levels could influence how SjD appears at diagnosis in a large international cohort of patients. The most notable relationships were found between symptoms (dryness and general body symptoms) and NO/SO, CO, and PM2.5 levels.
Published: 2023
Full Text: View/download PDF

50. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study.

Author: Brito-Zerón P, Flores-Chávez A, Horváth IF, Rasmussen A, Li X, Olsson P, Vissink A, Priori R, Armagan B, Hernandez-Molina G, Praprotnik S, Quartuccio L, Inanç N, Özkızıltaş B, Bartoloni E, Sebastian A, Romão VC, Solans R, Pasoto SG, Rischmueller M, Galisteo C, Suzuki Y, Trevisani VFM, Fugmann C, González-García A, Carubbi F, Jurcut C, Shimizu T, Retamozo S, Atzeni F, Hofauer B, Melchor-Díaz S, Gheita T, López-Dupla M, Fonseca-Aizpuru E, Giacomelli R, Vázquez M, Consani S, Akasbi M, Nakamura H, Szántó A, Farris AD, Wang L, Mandl T, Gattamelata A, Kilic L, Pirkmajer KP, Abacar K, Tufan A, de Vita S, Bootsma H, and Ramos-Casals M
Abstract: Background: What baseline predictors would be involved in mortality in people with primary Sjögren syndrome (SjS) remains uncertain. This study aimed to investigate the baseline characteristics collected at the time of diagnosis of SjS associated with mortality and to identify mortality risk factors for all-cause death and deaths related to systemic SjS activity measured by the ESSDAI score., Methods: In this international, real-world, retrospective, cohort study, we retrospectively collected data from 27 countries on mortality and causes of death from the Big Data Sjögren Registry. Inclusion criteria consisted of fulfilling 2002/2016 SjS classification criteria, and exclusion criteria included chronic HCV/HIV infections and associated systemic autoimmune diseases. A statistical approach based on a directed acyclic graph was used, with all-cause and Sjögren-related mortality as primary endpoints. The key determinants that defined the disease phenotype at diagnosis (glandular, systemic, and immunological) were analysed as independent variables., Findings: Between January 1st, 2014 and December 31, 2023, data from 11,372 patients with primary SjS (93.5% women, 78.4% classified as White, mean age at diagnosis of 51.1 years) included in the Registry were analysed. 876 (7.7%) deaths were recorded after a mean follow-up of 8.6 years (SD 7.12). Univariate analysis of prognostic factors for all-cause death identified eight Sjögren-related variables (ocular and oral tests, salivary biopsy, ESSDAI, ANA, anti-Ro, anti-La, and cryoglobulins). The multivariate CPH model adjusted for these variables and the epidemiological features showed that DAS-ESSDAI (high vs no high: HR = 1.68; 95% CI, 1.27-2.22) and cryoglobulins (positive vs negative: HR = 1.72; 95% CI, 1.22-2.42) were independent predictors of all-cause death. Of the 640 deaths with available information detailing the specific cause of death, 14% were due to systemic SjS. Univariate analysis of prognostic factors for Sjögren-cause death identified five Sjögren-related variables (oral tests, clinESSDAI, DAS-ESSDAI, ANA, and cryoglobulins). The multivariate competing risks CPH model adjusted for these variables and the epidemiological features showed that oral tests (abnormal vs normal results: HR = 1.38; 95% CI, 1.01-1.87), DAS-ESSDAI (high vs no high: HR = 1.55; 95% CI, 1.22-1.96) and cryoglobulins (positive vs negative: HR = 1.52; 95% CI, 1.16-2) were independent predictors of SjS-related death., Interpretation: The key mortality risk factors at the time of SjS diagnosis were positive cryoglobulins and a high systemic activity scored using the ESSDAI, conferring a 2-times increased risk of all-cause and SjS-related death. ESSDAI measurement and cryoglobulin testing should be considered mandatory when an individual is diagnosed with SjS., Funding: Novartis., Competing Interests: AR and ADF received the following Grant sor Contracts: R01 DE018209/DE/NIDCR NIH HHS/United States; U54 GM104938/GM/NIGMS NIH HHS/United States; P30 AR053483/AR/NIAMS NIH HHS/United States; P50 AR060804/AR/NIAMS NIH HHS/United States; R01 AR065953/AR/NIAMS NIH HHS/United States. ADF received the following Grants: R01 AR074310/NIAMS NIH HHS/United States; Janssen Research and Development, LLC. ADF reported the following patent: Antibody Tests for Identifying Ro Negative Sjögren's Syndrome and Use as Biomarkers for Dysregulated B Cell Responses, B Cell Lymphoma, Tissue Fibrosis and Salivary Gland Dysfunction. U.S. Patent application 17/797,619, filed August 4, 2022, European Patent application 21750408.3, filed September 14, 2022 and Canadian Patent application, filed September 14, 2022. FA received Grants from Pfizer & Novartis, payments or honoraria from Abbvie, Pfizer, Galapagos, Novartis, BMS, Boeringher, Janssen, and participated on Safety/Advisory Boards of Janssen and Boeringher. MR participated on Safety/Advisory Boards by Janssen and in clinical trials (BMS, Novartis, Servier). PO participated on Safety/Advisory Boards by Fresenius Kabi, Novartis & Boehringer Ingelheim. RG received Grants from Pfizer and Abbvie, payments/honoraria from Abbvie, Pfizer, MSD, Novartis, BMS and Boeringher, and participated on Safety/Advisory Boards by Abbvie, Pfizer, and Boeringher. SR participated on Safety/Advisory Boards by Janssen. TM declared that is working as medical advisor for UCB Pharma Sweden. VCR declared that is working as medical advisor for UCB Pharma Sweden. All other authors declare no competing interests., (© 2023 The Author(s).)
Published: 2023
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

95 results on '"Akasbi M"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources